



Clinical trial results:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis

Summary

| | |
|--------------------------|----------------------|
| EudraCT number | 2011-004350-26 |
| Trial protocol | DE CZ ES NL AT PL GB |
| Global end of trial date | 18 June 2019 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 25 June 2020 |
| First version publication date | 25 June 2020 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | I1F-MC-RHBA |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|---------------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01597245 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Trial Number: 12973 |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Eli Lilly and Company |
| Sponsor organisation address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Public contact | Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 877CTLilly, |
| Scientific contact | Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 8772854559, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 18 June 2019 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 18 June 2019 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------|
| Actual start date of recruitment | 18 May 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Czech Republic: 18 |
| Country: Number of subjects enrolled | Canada: 288 |
| Country: Number of subjects enrolled | Austria: 23 |
| Country: Number of subjects enrolled | Netherlands: 6 |
| Country: Number of subjects enrolled | Romania: 35 |
| Country: Number of subjects enrolled | United States: 369 |
| Country: Number of subjects enrolled | Poland: 102 |
| Country: Number of subjects enrolled | United Kingdom: 33 |
| Country: Number of subjects enrolled | Australia: 51 |
| Country: Number of subjects enrolled | France: 65 |
| Country: Number of subjects enrolled | Germany: 179 |
| Country: Number of subjects enrolled | Spain: 55 |
| Worldwide total number of subjects | 1224 |
| EEA total number of subjects | 516 |

Notes:

Subjects enrolled per age group

| | |
|----------|---|
| In utero | 0 |
|----------|---|

| | |
|---|------|
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 1147 |
| From 65 to 84 years | 77 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

No Text Available

Pre-assignment

Screening details:

This study has 5 periods: Period 1 - Screening; Period 2 - Blinded Induction Dosing Period (Weeks 0 to 12); Period 3 - Blinded Maintenance Dosing Period (Weeks 12 - 60); Period 4 - Long-Term Extension Period (Weeks 60 - 264); Period 5 - Post-Treatment Follow-Up Period (A Minimum of 12 Weeks)

Period 1

| | |
|------------------------------|--|
| Period 1 title | Induction Period (Week 0 - Week 12) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Carer, Assessor, Subject |

Arms

| | |
|------------------------------|----------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo - Induction Period |

Arm description:

Placebo was administered as 2 subcutaneous (SC) injections at week 0, followed by 1 injection at weeks 2, 4, 6, 8, 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo was administered as 2 subcutaneous (SC) injections at week 0, followed by 1 injection at weeks 2, 4, 6, 8, 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.

| | |
|------------------|---|
| Arm title | 50 mg Etanercept (ETN) - Induction Period |
|------------------|---|

Arm description:

50 milligrams (mg) ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixm was administered as 2 SC injections at Week 0 followed by Placebo for ixm administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).

| | |
|--|------------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Etanercept |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

50 milligrams (mg) ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12.

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |

| | |
|--------------------------|------------------|
| Routes of administration | Subcutaneous use |
|--------------------------|------------------|

Dosage and administration details:

Placebo for ixeluprel was administered as 2 SC injections at Week 0 followed by Placebo for ixeluprel administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).

| | |
|------------------|----------------------------------|
| Arm title | Ixeluprel Q4W - Induction Period |
|------------------|----------------------------------|

Arm description:

160 mg ixeluprel was administered as 2 SC injections at Week 0 followed by 80 mg ixeluprel as 1 SC injection every 4 weeks (Q4W:Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab (Ixe) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

160 mg ixeluprel was administered as 2 SC injections at Week 0 followed by 80 mg ixeluprel as 1 SC injection every 4 weeks (Q4W:Weeks 4 and 8).

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.

| | |
|------------------|----------------------------------|
| Arm title | Ixeluprel Q2W - Induction Period |
|------------------|----------------------------------|

Arm description:

160 mg ixeluprel administered as 2 SC injections at Week 0 followed by 80 mg ixeluprel as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

160 mg ixeluprel administered as 2 SC injections at Week 0 followed by 80 mg ixeluprel as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10.

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.

| Number of subjects in period 1 | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period |
|--|----------------------------|---|----------------------------|
| | | | |
| Started | 168 | 358 | 347 |
| Received at least 1 dose of study drug | 167 | 357 | 347 |
| Completed | 158 | 333 | 328 |
| Not completed | 10 | 25 | 19 |
| Consent withdrawn by subject | 2 | 8 | 6 |
| Physician decision | 1 | - | - |
| Adverse event, non-fatal | 1 | 5 | 5 |
| Lost to follow-up | 1 | 5 | 2 |
| Protocol deviation | 2 | 4 | 5 |
| Lack of efficacy | 3 | 3 | 1 |

| Number of subjects in period 1 | Ixe Q2W - Induction Period |
|--|----------------------------|
| Started | 351 |
| Received at least 1 dose of study drug | 350 |
| Completed | 342 |
| Not completed | 9 |
| Consent withdrawn by subject | 2 |
| Physician decision | 1 |
| Adverse event, non-fatal | 4 |
| Lost to follow-up | - |
| Protocol deviation | 2 |
| Lack of efficacy | - |

Period 2

| | |
|------------------------------|---|
| Period 2 title | Maintenance Period (Week 12 to Week 60) |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Carer, Assessor, Subject |

Arms

| | |
|------------------------------|--|
| Are arms mutually exclusive? | No |
| Arm title | Ixe/Placebo- Maintenance Period Primary Population (Pop) |

Arm description:

Participants who received 80 mg ixecicilumab Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56.

| | |
|----------|---------|
| Arm type | Placebo |
|----------|---------|

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixeluprel Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56

| | |
|------------------|--|
| Arm title | Ixeluprel/Q4W - Maintenance Period Primary Pop |
|------------------|--|

Arm description:

Participants who received 80 mg ixeluprel Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixeluprel as 1 SC injection and a Placebo for ixeluprel injection at Week 12 followed by 80 mg ixeluprel as 1 SC injection Q4W up to and including Week 56.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixeluprel Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixeluprel as 1 SC injection, Q4W from Weeks 12 - 56.

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo for ixeluprel injection at Week 12 followed by 80 mg ixeluprel as 1 SC injection Q4W up to and including Week 56.

| | |
|------------------|---|
| Arm title | Ixeluprel/Q12W - Maintenance Period Primary Pop |
|------------------|---|

Arm description:

Participants who received 80 mg ixeluprel Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixeluprel as 1 SC injection and a Placebo for ixeluprel injection at Week 12 followed by 80 mg ixeluprel as 1 SC injection every 12 weeks (Q12W) up to and including Week 56. To maintain blinding with Q4W dose regimen, Placebo for ixeluprel given as 1 SC injection at Weeks 16, 20, 28, 32, 40, 44, 52, and 56.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixeluprel Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixeluprel as 1 SC injection and followed by 80 mg ixeluprel as 1 SC injection every 12 weeks (Q12W) up to and including Week 56.

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo for ixeluprel injection at Week 12. To maintain blinding with Q4W dose regimen, Placebo for ixeluprel given

as 1 SC injection at Weeks 16, 20, 28, 32, 40, 44, 52, and 56.

| | |
|--|--|
| Arm title | Placebo Resp/Placebo - Maintenance Period Secondary Pop |
| Arm description: Participants who received placebo during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56. | |
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Participants who received placebo during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56 | |
| Arm title | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop |
| Arm description: Participants who received placebo in Induction Period (Weeks 0 to 10) and classified as non-responders (NonResp) were administered 160 mg ixm as 2 SC injections at Week 12 followed by 80 mg ixm as 1 SC injection Q4W up to and including Week 56. | |
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Participants who received placebo in Induction Period (Weeks 0 to 10) and classified as non-responders (NonResp) were administered 160 mg ixm as 2 SC injections at Week 12 followed by 80 mg ixm as 1 SC injection Q4W up to and including Week 56. | |
| Arm title | ETN Resp/Placebo Maintenance Period Secondary Pop |
| Arm description: Participants who received ETN during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56. | |
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: Participants who received ETN during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56. | |
| Arm title | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop |

Arm description:
Participants who received ETN in Induction Period (Weeks 0 to 12) and classified as non-responders were administered 2 SC injections of placebo at Week 12 followed by 80 mg ixm as 1 SC injection Q4W

up to and including Week 56.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

80 mg ixc as 1 SC injection Q4W from Weeks 16 - 60.

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

2 SC injections of placebo were administered at Week 12.

| | |
|------------------|---|
| Arm title | Ixc Q4W NonResp/Ixc Q4W- Maintenance Period Secondary Pop |
|------------------|---|

Arm description:

Participants who received 80 mg ixc Q4W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixc as 1 SC injection and a Placebo for ixc injection at Week 12 followed by 80 mg ixc as 1 SC injection Q4W up to and including Week 56.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixc Q4W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixc as 1 SC injection at Week 12 followed by 80 mg ixc as 1 SC injection Q4W up to and including Week 56.

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo for ixc injection at Week 12 followed by 80 mg ixc as 1 SC injection Q4W up to and including Week 56.

| | |
|------------------|--|
| Arm title | Ixc Q2W NonResp/Ixc Q4W - Maintenance Period Secondary Pop |
|------------------|--|

Arm description:

Participants who received 80 mg ixc Q2W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixc as 1 SC injection and a Placebo for ixc injection at Week 12 followed by 80 mg ixc as 1 SC injection Q4W up to and including Week 56.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixc Q2W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixc as 1 SC injection at Week 12 followed by 80 mg ixc as 1 SC

injection Q4W up to and including Week 56.

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo for ixeluprel injection at Week 12 followed by 80 mg ixeluprel as 1 SC injection Q4W up to and including Week 56.

| Number of subjects in period 2 | Ixeluprel/Placebo - Maintenance Period Primary Population (Pop) | Ixeluprel/Ixeluprel Q4W - Maintenance Period Primary Pop | Ixeluprel/Ixeluprel Q12W - Maintenance Period Primary Pop |
|--------------------------------|---|--|---|
| | Started | 176 | 187 |
| Participants received one dose | 176 | 187 | 181 |
| Completed | 15 | 149 | 92 |
| Not completed | 161 | 38 | 89 |
| Consent withdrawn by subject | 3 | 3 | 1 |
| Physician decision | - | 1 | - |
| Relapsed | 150 | 22 | 80 |
| Adverse event, non-fatal | 4 | 6 | 6 |
| On study treatment | - | 1 | 1 |
| Sponsor Decision | - | - | - |
| Lost to follow-up | 3 | 4 | 1 |
| Protocol deviation | 1 | - | - |
| Lack of efficacy | - | 1 | - |

| Number of subjects in period 2 | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo NonResp/Ixeluprel Q4W - Maintenance Period Secondary Pop | ETN Resp/Placebo Maintenance Period Secondary Pop |
|--------------------------------|---|--|---|
| | Started | 3 | 155 |
| Participants received one dose | 3 | 155 | 132 |
| Completed | 0 | 135 | 11 |
| Not completed | 3 | 20 | 121 |
| Consent withdrawn by subject | - | 4 | 1 |
| Physician decision | - | 1 | 1 |
| Relapsed | 2 | - | 114 |
| Adverse event, non-fatal | 1 | 8 | 2 |
| On study treatment | - | - | - |
| Sponsor Decision | - | - | - |
| Lost to follow-up | - | 1 | 2 |
| Protocol deviation | - | 3 | 1 |

| | | | |
|---------------------------------------|--|---|--|
| Lack of efficacy | - | 3 | - |
| Number of subjects in period 2 | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W NonResp/Ixe Q4W- Maintenance Period Secondary Pop | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary Pop |
| Started | 200 | 75 | 49 |
| Participants received one dose | 200 | 75 | 49 |
| Completed | 178 | 56 | 37 |
| Not completed | 22 | 19 | 12 |
| Consent withdrawn by subject | 6 | 5 | 4 |
| Physician decision | 1 | 1 | - |
| Relapsed | - | - | - |
| Adverse event, non-fatal | 8 | 1 | 2 |
| On study treatment | - | - | - |
| Sponsor Decision | 1 | - | - |
| Lost to follow-up | 2 | 2 | 1 |
| Protocol deviation | 2 | - | 1 |
| Lack of efficacy | 2 | 10 | 4 |

Period 3

| | |
|------------------------------|--|
| Period 3 title | Long Term Extension (Week 60 - Week 264) |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----------------------------------|
| Are arms mutually exclusive? | No |
| Arm title | Placebo Long-Term Extension (LTE) |

Arm description:

Participants who received placebo at the start of long-term extension period (Week 60) and could be switched to ixelumab. Data while participants were on placebo were included.

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received placebo at the start of long-term extension period (Week 60) and could be switched to ixelumab. Data while participants were on placebo were included.

| | |
|------------------|------------------------------|
| Arm title | Ixelumab Long-Term Extension |
|------------------|------------------------------|

Arm description:

Participants who received 80 mg ixelumab in all dosing regimens at the start of the long-term extension period from Week 60 to Week 264.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------------------|
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixekizumab in all dosing regimens at the start of the long-term extension period from Week 60 to Week 264.

| | |
|------------------|--------------------------------------|
| Arm title | Total Ixekizumab Long-term Extension |
|------------------|--------------------------------------|

Arm description:

Participants who received at least 1 dose of 80 mg ixekizumab in all dosing regimens during the long-term extension period from Week 60 to Week 264, including those who have switched from PBO to Ixekizumab in long-term extension (LTE) period.

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received at least 1 dose of 80 mg ixekizumab in all dosing regimens during the long-term extension period from Week 60 to Week 264, including those who have switched from PBO to Ixekizumab in long-term extension (LTE) period.

| Number of subjects in period 3 | Placebo Long-Term Extension (LTE) | Ixekizumab Long-Term Extension | Total Ixekizumab Long-term Extension |
|---------------------------------------|-----------------------------------|--------------------------------|--------------------------------------|
| Started | 26 | 979 | 1002 |
| Completed | 0 | 754 | 774 |
| Not completed | 26 | 225 | 228 |
| Adverse event, serious fatal | - | 8 | 8 |
| Consent withdrawn by subject | 1 | 62 | 63 |
| Physician decision | 1 | 11 | 12 |
| Clinical Relapse | - | 4 | 4 |
| Adverse event, non-fatal | 1 | 69 | 70 |
| Switched from PBO to Ixekizumab | 23 | - | - |
| Sponsor Decision | - | 1 | 1 |
| Lost to follow-up | - | 38 | 38 |
| Lack of efficacy | - | 26 | 26 |
| Protocol deviation | - | 6 | 6 |

Period 4

| | |
|------------------------------|--|
| Period 4 title | Post-Treatment Follow-Up (12 - 24 Weeks) |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|----------------------------------|
| Arm title | Placebo Post-Treatment Follow-Up |
|------------------|----------------------------------|

Arm description:

Participants who received PBO immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|----------|---------|
| Arm type | Placebo |
|----------|---------|

| | |
|--|---------|
| Investigational medicinal product name | Placebo |
|--|---------|

| | |
|--|--|
| Investigational medicinal product code | |
|--|--|

| | |
|------------|--|
| Other name | |
|------------|--|

| | |
|----------------------|-----------------------|
| Pharmaceutical forms | Solution for infusion |
|----------------------|-----------------------|

| | |
|--------------------------|------------------|
| Routes of administration | Subcutaneous use |
|--------------------------|------------------|

Dosage and administration details:

Participants who received PBO immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|------------------|------------------------------|
| Arm title | ETN Post-Treatment Follow-Up |
|------------------|------------------------------|

Arm description:

Participants who received ETN immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|--|-------------|
| Investigational medicinal product name | Etancercept |
|--|-------------|

| | |
|--|--|
| Investigational medicinal product code | |
|--|--|

| | |
|------------|--|
| Other name | |
|------------|--|

| | |
|----------------------|------------------------|
| Pharmaceutical forms | Solution for injection |
|----------------------|------------------------|

| | |
|--------------------------|------------------|
| Routes of administration | Subcutaneous use |
|--------------------------|------------------|

Dosage and administration details:

Participants who received ETN immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|------------------|-----------------------------------|
| Arm title | Ixe Q12W Post-Treatment Follow-Up |
|------------------|-----------------------------------|

Arm description:

Participants who received 80 mg ixeluprel 1 SC injection Q12W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------|
| Investigational medicinal product name | Ixekizumab |
|--|------------|

| | |
|--|--|
| Investigational medicinal product code | |
|--|--|

| | |
|------------|--|
| Other name | |
|------------|--|

| | |
|----------------------|------------------------|
| Pharmaceutical forms | Solution for injection |
|----------------------|------------------------|

| | |
|--------------------------|------------------|
| Routes of administration | Subcutaneous use |
|--------------------------|------------------|

Dosage and administration details:

Participants who received 80 mg ixeluprel 1 SC injection Q12W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|------------------|----------------------------------|
| Arm title | Ixe Q4W Post-Treatment Follow-Up |
|------------------|----------------------------------|

Arm description:

Participants who received 80 mg ixeluprel 1 SC injection Q4W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------------------|
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixekizumab 1 SC injection Q4W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|------------------|---|
| Arm title | Ixekizumab Q2W Post-Treatment Follow-Up |
|------------------|---|

Arm description:

Participants who received 80 mg ixekizumab 1 SC injection Q2W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Ixekizumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Participants who received 80 mg ixekizumab 1 SC injection Q2W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| Number of subjects in period 4 | Placebo Post-Treatment Follow-Up | ETN Post-Treatment Follow-Up | Ixekizumab Q12W Post-Treatment Follow-Up |
|---------------------------------------|----------------------------------|------------------------------|--|
| Started | 16 | 6 | 24 |
| Completed | 0 | 0 | 14 |
| Not completed | 16 | 6 | 10 |
| Physician decision | 1 | - | - |
| Consent withdrawn by subject | - | 1 | 1 |
| Clinical Relapse | - | - | - |
| Adverse event, non-fatal | 9 | 5 | 8 |
| Sponsor Decision | 1 | - | - |
| Lost to follow-up | - | - | 1 |
| Entry Criteria Not Met | 2 | - | - |
| Lack of efficacy | 2 | - | - |
| Protocol deviation | 1 | - | - |

| Number of subjects in period 4 | Ixekizumab Q4W Post-Treatment Follow-Up | Ixekizumab Q2W Post-Treatment Follow-Up |
|---------------------------------------|---|---|
| Started | 656 | 248 |
| Completed | 489 | 212 |
| Not completed | 167 | 36 |
| Physician decision | 9 | 1 |
| Consent withdrawn by subject | 41 | 13 |
| Clinical Relapse | 1 | - |
| Adverse event, non-fatal | 63 | 13 |

| | | |
|------------------------|----|---|
| Sponsor Decision | 1 | - |
| Lost to follow-up | 14 | 4 |
| Entry Criteria Not Met | 3 | - |
| Lack of efficacy | 29 | 3 |
| Protocol deviation | 6 | 2 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|----------------------------|
| Reporting group title | Placebo - Induction Period |
|-----------------------|----------------------------|

Reporting group description:

Placebo was administered as 2 subcutaneous (SC) injections at week 0, followed by 1 injection at weeks 2, 4, 6, 8, 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12.

| | |
|-----------------------|---|
| Reporting group title | 50 mg Etanercept (ETN) - Induction Period |
|-----------------------|---|

Reporting group description:

50 milligrams (mg) ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixelimumab was administered as 2 SC injections at Week 0 followed by Placebo for ixelimumab administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10).

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Ixelimumab Q4W - Induction Period |
|-----------------------|-----------------------------------|

Reporting group description:

160 mg ixelimumab was administered as 2 SC injections at Week 0 followed by 80 mg ixelimumab as 1 SC injection every 4 weeks (Q4W:Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Ixelimumab Q2W - Induction Period |
|-----------------------|-----------------------------------|

Reporting group description:

160 mg ixelimumab administered as 2 SC injections at Week 0 followed by 80 mg ixelimumab as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12.

| Reporting group values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixelimumab Q4W - Induction Period |
|--|----------------------------|---|-----------------------------------|
| Number of subjects | 168 | 358 | 347 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 159 | 337 | 324 |
| From 65-84 years | 9 | 21 | 23 |
| 85 years and over | 0 | 0 | 0 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 48 | 122 | 103 |
| Male | 120 | 236 | 244 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 11 | 26 | 24 |
| Not Hispanic or Latino | 130 | 279 | 271 |
| Unknown or Not Reported | 27 | 53 | 52 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 2 | 0 | 2 |

| | | | |
|--|---------|---------|---------|
| Asian | 6 | 8 | 11 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 |
| Black or African American | 10 | 13 | 11 |
| White | 149 | 331 | 315 |
| More than one race | 0 | 1 | 3 |
| Unknown or Not Reported | 0 | 4 | 4 |
| Region of Enrollment | | | |
| Units: Subjects | | | |
| Canada | 40 | 82 | 82 |
| Austria | 2 | 10 | 6 |
| Netherlands | 1 | 2 | 2 |
| Czechia | 3 | 6 | 3 |
| Romania | 6 | 9 | 8 |
| United States | 49 | 111 | 105 |
| Poland | 14 | 30 | 28 |
| United Kingdom | 4 | 9 | 9 |
| Australia | 7 | 13 | 15 |
| France | 7 | 18 | 21 |
| Germany | 28 | 53 | 51 |
| Spain | 7 | 15 | 17 |
| Baseline in Static Physician Global Assessment (sPGA) | | | |
| The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. The sPGA is recommended as an endpoint to use to assess efficacy in the treatment of Ps (EMA 2004). Overall lesions are categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's Ps is assessed at a given time point on a 6-point scale in which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate; 4 = severe, 5 = very severe. | | | |
| Units: Subjects | | | |
| sPGA = 3 | 86 | 186 | 166 |
| sPGA = 4, 5 | 82 | 172 | 181 |
| Baseline in Participants Achieving Psoriasis Area and Severity Index (PASI) Score | | | |
| PASI is another accepted primary efficacy measurement for this phase of development of Ps treatments. The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 20.57 | 19.07 | 20.04 |
| standard deviation | ± 8.366 | ± 6.701 | ± 6.962 |
| Baseline Dermatology-Specific Quality of Life Index (DLQI) Total Score | | | |
| DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 12.8 | 12.7 | 11.6 |
| standard deviation | ± 7.24 | ± 7.03 | ± 6.65 |
| Baseline in Nail Psoriasis Severity Index (NAPSI) Total Score | | | |
| The NAPSI scale evaluates Ps severity in the fingernail bed and fingernail matrix with each divided into quadrants. Scores range from 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum | | | |

| | | | |
|--|-------------------|-------------------|-------------------|
| of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80. Higher scores indicate more severe Ps. | | | |
| Units: units on a scale arithmetic mean standard deviation | 27.62 ± 20.937 | 30.44 ± 20.648 | 23.70 ± 18.696 |
| Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score | | | |
| The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). | | | |
| Units: units on a scale arithmetic mean standard deviation | 21.0 ± 15.24 | 20.0 ± 15.19 | 20.8 ± 15.63 |
| Baseline in Body Surface Area (BSA) Total Score | | | |
| BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participant's hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. | | | |
| Units: units on a scale arithmetic mean standard deviation | 27.2 ± 18.12 | 25.3 ± 15.50 | 27.0 ± 17.23 |
| Baseline in Quick Inventory of Depressive Symptomatology Self Report 16 items (QIDS-SR16) Score | | | |
| QIDS-SR16 is a participant-administered, 16-item instrument assesses the existence and severity of symptoms of depression. A participant is asked a statement relating to the way they have felt for the past 7 days and rate on a 4-point scale: 0 (best) to 3 (worst). The sum of the domains [sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance, decrease/increase in appetite/weight, and psychomotor agitation/retardation] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. | | | |
| Units: units on a scale arithmetic mean standard deviation | 4.7 ± 4.14 | 4.5 ± 4.07 | 4.4 ± 4.04 |
| Baseline in Patient's Global Assessment (PatGA) Total Score | | | |
| The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). | | | |
| Units: units on a scale arithmetic mean standard deviation | 4.0 ± 0.92 | 4.0 ± 0.96 | 4.1 ± 0.90 |
| Baseline in Work Productivity Activity Impairment - Psoriasis Absenteeism Score | | | |
| Units: units on a scale arithmetic mean standard deviation | 4.3 ± 16.61 | 3.7 ± 15.24 | 4.6 ± 17.65 |
| Baseline in Work Productivity Activity Impairment Questionnaire - Psoriasis Active Impairment Score | | | |
| Units: units on a scale arithmetic mean standard deviation | 30.2 ± 28.87 | 31.3 ± 29.04 | 29.4 ± 29.28 |
| Baseline in Work Productivity Impairment Questionnaire - Psoriasis Presenteeism Score | | | |

| | | | |
|---|-----------|-----------|-----------|
| Units: units on a scale | | | |
| arithmetic mean | 24.3 | 21.2 | 22.3 |
| standard deviation | ± 26.19 | ± 25.42 | ± 24.77 |
| Baseline in Work Productivity Activity Impairment Questionnaire-Psoriasis | | | |
| Work Productivity Loss | | | |
| Units: units on a scale | | | |
| arithmetic mean | 26.1 | 22.3 | 24.6 |
| standard deviation | ± 28.11 | ± 26.52 | ± 27.41 |
| Baseline in Short form (36 Items) Health Survey SF-36 Total Score | | | |
| The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the Physical Component Score (PCS) and Mental Component Score (MCS) scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. | | | |
| Physical Summary Score | | | |
| Units: units on a scale | | | |
| arithmetic mean | 47.7094 | 47.5268 | 47.6231 |
| standard deviation | ± 9.5043 | ± 9.0729 | ± 8.9693 |
| Baseline in SF-36 Total Score | | | |
| Mental Summary Score | | | |
| Units: units on a scale | | | |
| arithmetic mean | 47.7889 | 48.7097 | 49.0131 |
| standard deviation | ± 10.6183 | ± 10.6546 | ± 10.9087 |

| Reporting group values | Ixe Q2W - Induction Period | Total | |
|--|----------------------------|-------|--|
| Number of subjects | 351 | 1224 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 327 | 1147 | |
| From 65-84 years | 24 | 77 | |
| 85 years and over | 0 | 0 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 130 | 403 | |
| Male | 221 | 821 | |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 19 | 80 | |
| Not Hispanic or Latino | 274 | 954 | |
| Unknown or Not Reported | 58 | 190 | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |

| | | | |
|--|---------|------|--|
| American Indian or Alaska Native | 2 | 6 | |
| Asian | 12 | 37 | |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | |
| Black or African American | 5 | 39 | |
| White | 330 | 1125 | |
| More than one race | 1 | 5 | |
| Unknown or Not Reported | 1 | 9 | |
| Region of Enrollment | | | |
| Units: Subjects | | | |
| Canada | 84 | 288 | |
| Austria | 5 | 23 | |
| Netherlands | 1 | 6 | |
| Czechia | 6 | 18 | |
| Romania | 12 | 35 | |
| United States | 104 | 369 | |
| Poland | 30 | 102 | |
| United Kingdom | 11 | 33 | |
| Australia | 16 | 51 | |
| France | 19 | 65 | |
| Germany | 47 | 179 | |
| Spain | 16 | 55 | |
| Baseline in Static Physician Global Assessment (sPGA) | | | |
| The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. The sPGA is recommended as an endpoint to use to assess efficacy in the treatment of Ps (EMA 2004). Overall lesions are categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's Ps is assessed at a given time point on a 6-point scale in which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate; 4 = severe, 5 = very severe. | | | |
| Units: Subjects | | | |
| sPGA = 3 | 178 | 616 | |
| sPGA = 4, 5 | 173 | 608 | |
| Baseline in Participants Achieving Psoriasis Area and Severity Index (PASI) Score | | | |
| PASI is another accepted primary efficacy measurement for this phase of development of Ps treatments. The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 19.35 | | |
| standard deviation | ± 7.339 | - | |
| Baseline Dermatology-Specific Quality of Life Index (DLQI) Total Score | | | |
| DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 12.4 | | |
| standard deviation | ± 6.86 | - | |
| Baseline in Nail Psoriasis Severity Index (NAPSI) Total Score | | | |
| The NAPSI scale evaluates Ps severity in the fingernail bed and fingernail matrix with each divided into quadrants. Scores range from 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of | | | |

1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80. Higher scores indicate more severe Ps.

| | | | |
|-------------------------|----------|---|--|
| Units: units on a scale | | | |
| arithmetic mean | 26.27 | | |
| standard deviation | ± 20.388 | - | |

Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).

| | | | |
|-------------------------|---------|---|--|
| Units: units on a scale | | | |
| arithmetic mean | 19.5 | | |
| standard deviation | ± 14.85 | - | |

Baseline in Body Surface Area (BSA) Total Score

BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participant's hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas.

| | | | |
|-------------------------|---------|---|--|
| Units: units on a scale | | | |
| arithmetic mean | 25.1 | | |
| standard deviation | ± 15.82 | - | |

Baseline in Quick Inventory of Depressive Symptomatology Self Report 16 items (QIDS-SR16) Score

QIDS-SR16 is a participant-administered, 16-item instrument assesses the existence and severity of symptoms of depression. A participant is asked a statement relating to the way they have felt for the past 7 days and rate on a 4-point scale: 0 (best) to 3 (worst). The sum of the domains [sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance, decrease/increase in appetite/weight, and psychomotor agitation/retardation] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.

| | | | |
|-------------------------|--------|---|--|
| Units: units on a scale | | | |
| arithmetic mean | 4.6 | | |
| standard deviation | ± 3.84 | - | |

Baseline in Patient's Global Assessment (PatGA) Total Score

The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been).

| | | | |
|-------------------------|--------|---|--|
| Units: units on a scale | | | |
| arithmetic mean | 4.1 | | |
| standard deviation | ± 0.91 | - | |

Baseline in Work Productivity Activity Impairment - Psoriasis

Absenteeism Score

| | | | |
|-------------------------|---------|---|--|
| Units: units on a scale | | | |
| arithmetic mean | 7.3 | | |
| standard deviation | ± 22.15 | - | |

Baseline in Work Productivity Activity Impairment Questionnaire - Psoriasis

Active Impairment Score

| | | | |
|-------------------------|---------|---|--|
| Units: units on a scale | | | |
| arithmetic mean | 31.7 | | |
| standard deviation | ± 29.64 | - | |

Baseline in Work Productivity

| | | | |
|--|-----------|---|--|
| Impairment Questionnaire - Psoriasis | | | |
| Presenteeism Score | | | |
| Units: units on a scale | | | |
| arithmetic mean | 24.2 | | |
| standard deviation | ± 25.80 | - | |
| Baseline in Work Productivity Activity Impairment Questionnaire-Psoriasis | | | |
| Work Productivity Loss | | | |
| Units: units on a scale | | | |
| arithmetic mean | 27.7 | | |
| standard deviation | ± 29.19 | - | |
| Baseline in Short form (36 Items) Health Survey SF-36 Total Score | | | |
| <p>The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the Physical Component Score (PCS) and Mental Component Score (MCS) scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.</p> | | | |
| Physical Summary Score | | | |
| Units: units on a scale | | | |
| arithmetic mean | 47.6996 | | |
| standard deviation | ± 9.03332 | - | |
| Baseline in SF-36 Total Score | | | |
| Mental Summary Score | | | |
| Units: units on a scale | | | |
| arithmetic mean | 47.7140 | | |
| standard deviation | ± 11.6686 | - | |

Subject analysis sets

| | |
|---------------------------------------|--------------------|
| Subject analysis set title | Total Participants |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| All participants with evaluable data. | |

| | | | |
|--|--------------------|--|--|
| Reporting group values | Total Participants | | |
| Number of subjects | 1224 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |

| | | | |
|--|------------------|--|--|
| Gender categorical Units: Subjects | | | |
| Female Male | | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino Not Hispanic or Latino Unknown or Not Reported | | | |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported | | | |
| Region of Enrollment Units: Subjects | | | |
| Canada Austria Netherlands Czechia Romania United States Poland United Kingdom Australia France Germany Spain | | | |
| Baseline in Static Physician Global Assessment (sPGA) | | | |
| The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. The sPGA is recommended as an endpoint to use to assess efficacy in the treatment of Ps (EMA 2004). Overall lesions are categorized by descriptions for induration, erythema, and scaling. For the analysis of responses, the participant's Ps is assessed at a given time point on a 6-point scale in which 0 = cleared, 1 = minimal, 2 = mild, 3 = moderate; 4 = severe, 5 = very severe. | | | |
| Units: Subjects | | | |
| sPGA = 3 sPGA = 4, 5 | | | |
| Baseline in Participants Achieving Psoriasis Area and Severity Index (PASI) Score | | | |
| PASI is another accepted primary efficacy measurement for this phase of development of Ps treatments. The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 or no Ps to 72 for the most severe disease. | | | |
| Units: units on a scale arithmetic mean standard deviation | 19.63 ± 7.216 | | |
| Baseline Dermatology-Specific Quality of | | | |

| | | | |
|--|----------|--|--|
| Life Index (DLQI) Total Score | | | |
| DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered ("not relevant") responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 12.3 | | |
| standard deviation | ± 6.91 | | |
| Baseline in Nail Psoriasis Severity Index (NAPSI) Total Score | | | |
| The NAPSI scale evaluates Ps severity in the fingernail bed and fingernail matrix with each divided into quadrants. Scores range from 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80. Higher scores indicate more severe Ps. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 26.97 | | |
| standard deviation | ± 20.211 | | |
| Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score | | | |
| The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). | | | |
| Units: units on a scale | | | |
| arithmetic mean | 20.2 | | |
| standard deviation | ± 15.22 | | |
| Baseline in Body Surface Area (BSA) Total Score | | | |
| BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), where 1% corresponds to the size of the participant's hand (includes the palm, fingers and thumb). Total BSA is the sum of handprints from the affected areas. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 26.0 | | |
| standard deviation | ± 16.47 | | |
| Baseline in Quick Inventory of Depressive Symptomatology Self Report 16 items (QIDS-SR16) Score | | | |
| QIDS-SR16 is a participant-administered, 16-item instrument assesses the existence and severity of symptoms of depression. A participant is asked a statement relating to the way they have felt for the past 7 days and rate on a 4-point scale: 0 (best) to 3 (worst). The sum of the domains [sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance, decrease/increase in appetite/weight, and psychomotor agitation/retardation] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. | | | |
| Units: units on a scale | | | |
| arithmetic mean | 4.5 | | |
| standard deviation | ± 4.00 | | |
| Baseline in Patient's Global Assessment (PatGA) Total Score | | | |
| The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). | | | |
| Units: units on a scale | | | |
| arithmetic mean | 4.0 | | |
| standard deviation | ± 0.92 | | |
| Baseline in Work Productivity Activity | | | |

| | | | |
|--|----------------------|--|--|
| Impairment - Psoriasis | | | |
| Absenteeism Score | | | |
| Units: units on a scale arithmetic mean standard deviation | 5.1 ± 18.40 | | |
| Baseline in Work Productivity Activity Impairment Questionnaire - Psoriasis | | | |
| Active Impairment Score | | | |
| Units: units on a scale arithmetic mean standard deviation | 30.7 ± 29.24 | | |
| Baseline in Work Productivity Impairment Questionnaire - Psoriasis | | | |
| Presenteeism Score | | | |
| Units: units on a scale arithmetic mean standard deviation | 22.8 ± 25.44 | | |
| Baseline in Work Productivity Activity Impairment Questionnaire-Psoriasis | | | |
| Work Productivity Loss | | | |
| Units: units on a scale arithmetic mean standard deviation | 25.0 ± 27.82 | | |
| Baseline in Short form (36 Items) Health Survey SF-36 Total Score | | | |
| <p>The SF-36 is a self-reported instrument that measures the participant's health status during the previous 7 days. It comprises 36-items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped in the Physical Component Score (PCS) and Mental Component Score (MCS) scores. Scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.</p> | | | |
| Physical Summary Score | | | |
| Units: units on a scale arithmetic mean standard deviation | 47.6289 ± 9.0814 | | |
| Baseline in SF-36 Total Score | | | |
| Mental Summary Score | | | |
| Units: units on a scale arithmetic mean standard deviation | 48.3832 ± 11.0234 | | |

End points

End points reporting groups

| | |
|---|---|
| Reporting group title | Placebo - Induction Period |
| Reporting group description: Placebo was administered as 2 subcutaneous (SC) injections at week 0, followed by 1 injection at weeks 2, 4, 6, 8, 10. Placebo for ETN (1 SC injection) administered twice weekly (every 3 to 4 days) starting at Week 0 up to Week 12. | |
| Reporting group title | 50 mg Etanercept (ETN) - Induction Period |
| Reporting group description: 50 milligrams (mg) ETN was administered by 1 SC injection twice weekly (every 3-4 days) up to Week 12. Placebo for ixelimumab (ixe) was administered as 2 SC injections at Week 0 followed by Placebo for ixelimumab administered as 1 SC injection Q2W (Weeks 2, 4, 6, 8, and 10). | |
| Reporting group title | Ixelimumab (ixe) Q4W - Induction Period |
| Reporting group description: 160 mg ixelimumab was administered as 2 SC injections at Week 0 followed by 80 mg ixelimumab as 1 SC injection every 4 weeks (Q4W:Weeks 4 and 8). Placebo was administered as 1 SC injection at Weeks 2, 6, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12. | |
| Reporting group title | Ixelimumab (ixe) Q2W - Induction Period |
| Reporting group description: 160 mg ixelimumab administered as 2 SC injections at Week 0 followed by 80 mg ixelimumab as 1 SC injection Q2W at Weeks 2, 4, 6, 8, and 10. Placebo for ETN (1 SC injection) was administered twice weekly starting at Week 0 up to Week 12. | |
| Reporting group title | Ixelimumab/Placebo- Maintenance Period Primary Population (Pop) |
| Reporting group description: Participants who received 80 mg ixelimumab Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56. | |
| Reporting group title | Ixelimumab/Ixelimumab Q4W - Maintenance Period Primary Pop |
| Reporting group description: Participants who received 80 mg ixelimumab Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixelimumab as 1 SC injection and a Placebo for ixelimumab injection at Week 12 followed by 80 mg ixelimumab as 1 SC injection Q4W up to and including Week 56. | |
| Reporting group title | Ixelimumab/Ixelimumab Q12W - Maintenance Period Primary Pop |
| Reporting group description: Participants who received 80 mg ixelimumab Q2W or Q4W in Induction Period (Weeks 0 to 10) and classified as responders were administered 80 mg ixelimumab as 1 SC injection and a Placebo for ixelimumab injection at Week 12 followed by 80 mg ixelimumab as 1 SC injection every 12 weeks (Q12W) up to and including Week 56. To maintain blinding with Q4W dose regimen, Placebo for ixelimumab given as 1 SC injection at Weeks 16, 20, 28, 32, 40, 44, 52, and 56. | |
| Reporting group title | Placebo Resp/Placebo - Maintenance Period Secondary Pop |
| Reporting group description: Participants who received placebo during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56. | |
| Reporting group title | Placebo NonResp/Ixelimumab Q4W - Maintenance Period Secondary Pop |
| Reporting group description: Participants who received placebo in Induction Period (Weeks 0 to 10) and classified as non-responders (NonResp) were administered 160 mg ixelimumab as 2 SC injections at Week 12 followed by 80 mg ixelimumab as 1 SC injection Q4W up to and including Week 56. | |
| Reporting group title | ETN Resp/Placebo Maintenance Period Secondary Pop |
| Reporting group description: Participants who received ETN during the Induction Period (Weeks 0 to 10) and classified as responders and were administered placebo as 2 SC injections at Week 12 followed by placebo as 1 SC injection Q4W up to and including Week 56. | |
| Reporting group title | ETN NonResp/Ixelimumab Q4W - Maintenance Period Secondary Pop |

Reporting group description:

Participants who received ETN in Induction Period (Weeks 0 to 12) and classified as non-responders were administered 2 SC injections of placebo at Week 12 followed by 80 mg ixeluprel as 1 SC injection Q4W up to and including Week 56.

| | |
|-----------------------|---|
| Reporting group title | Ixeluprel Q4W NonResp/Ixeluprel Q4W- Maintenance Period Secondary Pop |
|-----------------------|---|

Reporting group description:

Participants who received 80 mg ixeluprel Q4W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixeluprel as 1 SC injection and a Placebo for ixeluprel injection at Week 12 followed by 80 mg ixeluprel as 1 SC injection Q4W up to and including Week 56.

| | |
|-----------------------|--|
| Reporting group title | Ixeluprel Q2W NonResp/Ixeluprel Q4W - Maintenance Period Secondary Pop |
|-----------------------|--|

Reporting group description:

Participants who received 80 mg ixeluprel Q2W in Induction Period (Weeks 0 to 10) and classified as non-responders were administered 80 mg ixeluprel as 1 SC injection and a Placebo for ixeluprel injection at Week 12 followed by 80 mg ixeluprel as 1 SC injection Q4W up to and including Week 56.

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Placebo Long-Term Extension (LTE) |
|-----------------------|-----------------------------------|

Reporting group description:

Participants who received placebo at the start of long-term extension period (Week 60) and could be switched to ixeluprel. Data while participants were on placebo were included.

| | |
|-----------------------|-------------------------------|
| Reporting group title | Ixeluprel Long-Term Extension |
|-----------------------|-------------------------------|

Reporting group description:

Participants who received 80 mg ixeluprel in all dosing regimens at the start of the long-term extension period from Week 60 to Week 264.

| | |
|-----------------------|-------------------------------------|
| Reporting group title | Total Ixeluprel Long-term Extension |
|-----------------------|-------------------------------------|

Reporting group description:

Participants who received at least 1 dose of 80 mg ixeluprel in all dosing regimens during the long-term extension period from Week 60 to Week 264, including those who have switched from PBO to Ixeluprel in long-term extension (LTE) period.

| | |
|-----------------------|----------------------------------|
| Reporting group title | Placebo Post-Treatment Follow-Up |
|-----------------------|----------------------------------|

Reporting group description:

Participants who received PBO immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|-----------------------|------------------------------|
| Reporting group title | ETN Post-Treatment Follow-Up |
|-----------------------|------------------------------|

Reporting group description:

Participants who received ETN immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|-----------------------|---|
| Reporting group title | Ixeluprel Q12W Post-Treatment Follow-Up |
|-----------------------|---|

Reporting group description:

Participants who received 80 mg ixeluprel 1 SC injection Q12W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|-----------------------|--|
| Reporting group title | Ixeluprel Q4W Post-Treatment Follow-Up |
|-----------------------|--|

Reporting group description:

Participants who received 80 mg ixeluprel 1 SC injection Q4W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|-----------------------|--|
| Reporting group title | Ixeluprel Q2W Post-Treatment Follow-Up |
|-----------------------|--|

Reporting group description:

Participants who received 80 mg ixeluprel 1 SC injection Q2W immediately prior to entering the Post-Treatment Follow-Up period (a 12-24 week period after their last scheduled treatment visit).

| | |
|----------------------------|--------------------|
| Subject analysis set title | Total Participants |
|----------------------------|--------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

All participants with evaluable data.

Primary: Percentage of Participants with a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis. Measure: Static Physician Global Assessment [sPGA])

| | |
|-----------------|--|
| End point title | Percentage of Participants with a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis. Measure: Static Physician Global Assessment [sPGA]) |
|-----------------|--|

End point description:

The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for Non-Responder Imputation (NRI) analysis.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 168 ^[1] | 358 ^[2] | 347 ^[3] | 351 ^[4] |
| Units: percentage of participants | | | | |
| number (not applicable) | 2.4 | 36.0 | 72.9 | 83.2 |

Notes:

- [1] - All randomized participants.
- [2] - All randomized participants.
- [3] - All randomized participants.
- [4] - All randomized participants.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | sPGA Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 526 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|-----------------------------------|---|
| Statistical analysis title | sPGA Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 515 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | sPGA Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 519 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

Primary: Percentage of Participants achieving Psoriasis Area and Severity Index (PASI) \geq 75% (PASI75) Improvement (Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis. Measure: Psoriasis Area and Severity Index [PASI])

| | |
|-----------------|--|
| End point title | Percentage of Participants achieving Psoriasis Area and Severity Index (PASI) \geq 75% (PASI75) Improvement (Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis. Measure: Psoriasis Area and Severity Index [PASI]) |
|-----------------|--|

End point description:

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of \geq 75% in the PASI score compared to baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.

| | |
|----------------------|---------|
| End point type | Primary |
| End point timeframe: | Week 12 |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 168 ^[5] | 358 ^[6] | 347 ^[7] | 351 ^[8] |
| Units: percentage of participants | | | | |
| number (not applicable) | 2.4 | 41.6 | 77.5 | 89.7 |

Notes:

[5] - All randomized participants.

[6] - All randomized participants.

[7] - All randomized participants.

[8] - All randomized participants.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | PASI75 Statistical Analysis 1 |
| Comparison groups | 50 mg Etanercept (ETN) - Induction Period v Placebo - Induction Period |
| Number of subjects included in analysis | 526 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PASI75 Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 515 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PASI75 Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 519 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

Secondary: Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])

| | |
|-----------------|---|
| End point title | Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA]) |
|-----------------|---|

End point description:

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 168 ^[9] | 358 ^[10] | 347 ^[11] | 351 ^[12] |
| Units: percentage of participants | | | | |
| number (not applicable) | 0.6 | 5.9 | 32.3 | 41.9 |

Notes:

[9] - All randomized participants.

[10] - All randomized participants.

[11] - All randomized participants.

[12] - All randomized participants.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | sPGA (0) Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 526 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.005 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | sPGA (0) Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 515 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|-----------------------------------|---|
| Statistical analysis title | sPGA (0) Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 519 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

Secondary: Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis. Measure: [PASI])

| | |
|-----------------|---|
| End point title | Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis. Measure: [PASI]) |
|-----------------|---|

End point description:

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of $\geq 90\%$ in the PASI score compared to baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | Week 12 |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 168 ^[13] | 358 ^[14] | 347 ^[15] | 351 ^[16] |
| Units: percentage of participants | | | | |
| number (not applicable) | 0.6 | 18.7 | 59.7 | 70.7 |

Notes:

[13] - All randomized participants.

[14] - All randomized participants.

[15] - All randomized participants.

[16] - All randomized participants.

Statistical analyses

| | |
|----------------------------|--|
| Statistical analysis title | PASI90 Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 526 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PASI90 Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 515 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PASI90 Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 519 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

Secondary: Percentage of Participants Achieving PASI 100% (PASI100)

| | |
|-----------------|--|
| End point title | Percentage of Participants Achieving PASI 100% (PASI100) |
|-----------------|--|

End point description:

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor (head [0.1], upper limbs [0.2], trunk [0.3], lower limbs [0.4]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 168 ^[17] | 358 ^[18] | 347 ^[19] | 351 ^[20] |
| Units: percentage of participants | | | | |
| number (not applicable) | 0.6 | 5.3 | 30.8 | 40.5 |

Notes:

[17] - All randomized participants.

[18] - All randomized participants.

[19] - All randomized participants.

[20] - All randomized participants.

Statistical analyses

| Statistical analysis title | PASI100 Statistical Analysis 1 |
|---|--|
| Comparison groups | 50 mg Etanercept (ETN) - Induction Period v Placebo - Induction Period |
| Number of subjects included in analysis | 526 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.008 |
| Method | Cochran-Mantel-Haenszel |

| Statistical analysis title | PASI100 Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 515 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| Statistical analysis title | PASI100 Statistical Analysis 3 |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 519 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

Secondary: Percentage of Participants Maintaining an sPGA (0,1) from Week 12 after Re-randomization at start of Maintenance Dosing Period to Week 60

| | |
|-----------------|---|
| End point title | Percentage of Participants Maintaining an sPGA (0,1) from Week 12 after Re-randomization at start of Maintenance Dosing |
|-----------------|---|

End point description:

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

| | |
|----------------------|---------|
| End point timeframe: | Week 60 |
|----------------------|---------|

| End point values | Ixe/Placebo-Maintenance Period Primary Population (Pop) | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | |
|-----------------------------------|---|--|---|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 176 ^[21] | 187 ^[22] | 181 ^[23] | |
| Units: Percentage of participants | | | | |
| number (not applicable) | 6.3 | 74.9 | 40.9 | |

Notes:

[21] - All randomized participants who had sPGA score of (0,1), re-randomized, and received drug.

[22] - All randomized participants who had sPGA score of (0,1), re-randomized, and received drug.

[23] - All randomized participants who had sPGA score of (0,1), re-randomized, and received drug.

Statistical analyses

| Statistical analysis title | sPGA (0,1) Statistical Analysis 1 |
|---|---|
| Comparison groups | Ixe/Ixe Q12W - Maintenance Period Primary Pop v Ixe/Placebo-Maintenance Period Primary Population (Pop) |
| Number of subjects included in analysis | 357 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Fisher exact |

| Statistical analysis title | sPGA (0,1) Statistical Analysis 2 |
|---|---|
| Comparison groups | Ixe/Placebo- Maintenance Period Primary Population (Pop) v Ixe/Ixe Q4W - Maintenance Period Primary Pop |
| Number of subjects included in analysis | 363 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Fisher exact |

Secondary: Percentage of Participants with Itching Severity (Itch Numeric Rating Scale [NRI]) Score \geq 4 Point Reduction from Baseline

| | |
|------------------------|--|
| End point title | Percentage of Participants with Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥ 4 Point Reduction from Baseline |
| End point description: | The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable". The number and percentage of participants achieving an Itch NRS ≥ 4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥ 4 . Describes worst level of itching in past 24 hours. Participants who did not meet the clinical response criteria or had missing data at Week 12 were considered non-responders for NRI analysis. |
| End point type | Secondary |
| End point timeframe: | Week 12 |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 135 ^[24] | 306 ^[25] | 293 ^[26] | 303 ^[27] |
| Units: percentage of participants | | | | |
| number (not applicable) | 14.1 | 57.8 | 76.8 | 85.1 |

Notes:

[24] - All randomized participants who had Itch NRS ≥ 4 at baseline.

[25] - All randomized participants who had Itch NRS ≥ 4 at baseline.

[26] - All randomized participants who had Itch NRS ≥ 4 at baseline.

[27] - All randomized participants who had Itch NRS ≥ 4 at baseline.

Statistical analyses

| Statistical analysis title | Itch NRI Score Statistical Analysis 1 |
|---|--|
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 441 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| Statistical analysis title | Itch NRI Score Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 428 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | Itch NRI Score Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 438 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

Secondary: Change from baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])

| | |
|-----------------|--|
| End point title | Change from baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO]) |
|-----------------|--|

End point description:

DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and "not relevant" and unanswered responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 160 ^[28] | 346 ^[29] | 338 ^[30] | 343 ^[31] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | -2.0 (± 0.36) | -7.7 (± 0.25) | -9.4 (± 0.25) | -10.4 (± 0.25) |

Notes:

[28] - All randomized participants who had baseline and at least 1 post-baseline DLQI measurement.

[29] - All randomized participants who had baseline and at least 1 post-baseline DLQI measurement.

[30] - All randomized participants who had baseline and at least 1 post-baseline DLQI measurement.

[31] - All randomized participants who had baseline and at least 1 post-baseline DLQI measurement.

Statistical analyses

| | |
|-----------------------------------|--|
| Statistical analysis title | DLQI Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |

| | |
|---|-----------------------|
| Number of subjects included in analysis | 506 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | DLQI Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 498 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | DLQI Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 503 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

Secondary: Change from Baseline in Nail Psoriasis Severity Index (NAPSI)

| | |
|-----------------|---|
| End point title | Change from Baseline in Nail Psoriasis Severity Index (NAPSI) |
|-----------------|---|

End point description:

The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 111 ^[32] | 219 ^[33] | 215 ^[34] | 206 ^[35] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | -0.82 (± 1.162) | -5.34 (± 0.835) | -7.39 (± 0.843) | -8.60 (± 0.853) |

Notes:

[32] - All randomized participants with fingernail Ps involvement at baseline and had ≥1 post-baseline.

[33] - All randomized participants with fingernail Ps involvement at baseline and had ≥1 post-baseline.

[34] - All randomized participants with fingernail Ps involvement at baseline and had ≥1 post-baseline.

[35] - All randomized participants with fingernail Ps involvement at baseline and had ≥1 post-baseline.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | NAPSI Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 330 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.002 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | NAPSI Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 326 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | NAPSI Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 317 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

Secondary: Change from Baseline Psoriasis Scalp Severity Index (PSSI) Score

| | |
|-----------------|--|
| End point title | Change from Baseline Psoriasis Scalp Severity Index (PSSI) Score |
|-----------------|--|

End point description:

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (<10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects. Missing data was imputed by last observation carried forward (LOCF).

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Week 12 | |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 150 ^[36] | 316 ^[37] | 307 ^[38] | 318 ^[39] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | -3.8 (± 0.73) | -14.8 (± 0.50) | -18.5 (± 0.51) | -18.7 (± 0.50) |

Notes:

[36] - All randomized participants with scalp Ps involvement at baseline and had at least 1 post-baseline.

[37] - All randomized participants with scalp Ps involvement at baseline and had at least 1 post-baseline.

[38] - All randomized participants with scalp Ps involvement at baseline and had at least 1 post-baseline.

[39] - All randomized participants with scalp Ps involvement at baseline and had at least 1 post-baseline.

Statistical analyses

| Statistical analysis title | PSSI Statistical Analysis 1 |
|---|--|
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 466 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| Statistical analysis title | PSSI Statistical Analysis 2 |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 457 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | PSSI Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 468 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

Secondary: Change from Baseline in Percent of Body Surface Area (BSA) involvement of psoriasis

| | |
|------------------------|--|
| End point title | Change from Baseline in Percent of Body Surface Area (BSA) involvement of psoriasis |
| End point description: | The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects. |
| End point type | Secondary |
| End point timeframe: | Baseline, Week 12 |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 166 ^[40] | 350 ^[41] | 342 ^[42] | 348 ^[43] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | 0.5 (± 1.05) | -12.4 (± 0.72) | -20.3 (± 0.72) | -20.6 (± 0.71) |

Notes:

[40] - All randomized participants who had at least 1 post-baseline BSA measurement.

[41] - All randomized participants who had at least 1 post-baseline BSA measurement.

[42] - All randomized participants who had at least 1 post-baseline BSA measurement.

[43] - All randomized participants who had at least 1 post-baseline BSA measurement.

Statistical analyses

| | |
|-----------------------------------|--|
| Statistical analysis title | BSA Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |

| | |
|---|-----------------------|
| Number of subjects included in analysis | 516 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | BSA Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 508 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | BSA Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 514 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

Secondary: Change from baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 items (QIDS-SR16) Total Score

| | |
|-----------------|---|
| End point title | Change from baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 items (QIDS-SR16) Total Score |
|-----------------|---|

End point description:

The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance [initial, middle and late insomnia or hypersomnia], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score. Missing data was imputed by last observation carried forward (LOCF).

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Week 12 | |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 162 ^[44] | 342 ^[45] | 334 ^[46] | 347 ^[47] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | 0.1 (± 0.21) | -0.3 (± 0.15) | -0.7 (± 0.15) | -0.9 (± 0.15) |

Notes:

[44] - All randomized participants who had baseline and at least 1 post baseline QIDS-SR16 measurement

[45] - All randomized participants who had baseline and at least 1 post baseline QIDS-SR16 measurement

[46] - All randomized participants who had baseline and at least 1 post baseline QIDS-SR16 measurement

[47] - All randomized participants who had baseline and at least 1 post baseline QIDS-SR16 measurement

Statistical analyses

| | |
|---|--|
| Statistical analysis title | QIDS-SR16 Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 504 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.15 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | QIDS-SR16 Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 496 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.002 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | QIDS-SR16 Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 509 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

Secondary: Change from Baseline in Absenteeism of Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)

| | |
|------------------------|--|
| End point title | Change from Baseline in Absenteeism of Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO) |
| End point description: | The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score * 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value. Missing data was imputed by last observation carried forward (LOCF). |
| End point type | Secondary |
| End point timeframe: | Baseline, Week 12 |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 87 ^[48] | 199 ^[49] | 204 ^[50] | 213 ^[51] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | | | | |
| Absenteeism | -1.5 (± 0.83) | -3.7 (± 0.55) | -3.2 (± 0.54) | -3.9 (± 0.54) |

Notes:

[48] - All randomized participants who had baseline and at least 1 post baseline WPAI-PSO Absenteeism.

[49] - All randomized participants who had baseline and at least 1 post baseline WPAI-PSO Absenteeism.

[50] - All randomized participants who had baseline and at least 1 post baseline WPAI-PSO Absenteeism.

[51] - All randomized participants who had baseline and at least 1 post baseline WPAI-PSO Absenteeism.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | WPAI-PSO Statistical Analysis 1 |
| Statistical analysis description: | Absenteeism Score |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 286 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[52] |
| P-value | = 0.026 |
| Method | ANCOVA |

Notes:

[52] - Absenteeism Score

| | |
|-----------------------------------|---------------------------------|
| Statistical analysis title | WPAI-PSO Statistical Analysis 2 |
| Statistical analysis description: | Absenteeism Score |

| | |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 291 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[53] |
| P-value | = 0.076 |
| Method | ANCOVA |

Notes:

[53] - Absenteeism Score

| | |
|-----------------------------------|---------------------------------|
| Statistical analysis title | WPAI-PSO Statistical Analysis 3 |
|-----------------------------------|---------------------------------|

Statistical analysis description:

Absenteeism Score

| | |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 300 |
| Analysis specification | Pre-specified |
| Analysis type | superiority ^[54] |
| P-value | = 0.016 |
| Method | ANCOVA |

Notes:

[54] - Absenteeism Score

Secondary: Change From Baseline in Activity Impairment Score of WPAI-PSO

| | |
|-----------------|---|
| End point title | Change From Baseline in Activity Impairment Score of WPAI-PSO |
|-----------------|---|

End point description:

The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score * 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value. Missing data was imputed by last observation carried forward (LOCF).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 160 ^[55] | 342 ^[56] | 332 ^[57] | 340 ^[58] |
| Units: units on a scale | | | | |
| least squares mean (standard deviation) | | | | |
| Activity Impairment Score | -0.4 (± 1.46) | -16.6 (± 1.00) | -22.6 (± 1.02) | -25.8 (± 1.01) |

Notes:

[55] - All randomized participants who had baseline and at least 1 post baseline activity impairment score.

[56] - All randomized participants who had baseline and at least 1 post baseline activity impairment score.

[57] - All randomized participants who had baseline and at least 1 post baseline activity impairment score.

[58] - All randomized participants who had baseline and at least 1 post baseline activity impairment score.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | WPAI-PSO Statistical Analysis 4 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 502 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | WPAI-PSO Statistical Analysis 5 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 492 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | WPAI-PSO Statistical Analysis 6 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 500 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

Secondary: Change From Baseline in Presenteeism Score of WPAI-PSO

| | |
|------------------------|--|
| End point title | Change From Baseline in Presenteeism Score of WPAI-PSO |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Week 12 | |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 94 ^[59] | 217 ^[60] | 226 ^[61] | 232 ^[62] |
| Units: units on a scale | | | | |
| least squares mean (standard deviation) | | | | |
| Presenteeism Score | -2.4 (± 1.59) | -12.4 (± 1.05) | -18.5 (± 1.03) | -18.2 (± 1.03) |

Notes:

[59] - All randomized participants who had baseline and at least 1 post baseline presenteeism measurement.

[60] - All randomized participants who had baseline and at least 1 post baseline presenteeism measurement.

[61] - All randomized participants who had baseline and at least 1 post baseline presenteeism measurement.

[62] - All randomized participants who had baseline and at least 1 post baseline presenteeism measurement

Statistical analyses

| Statistical analysis title | WPAI-PSO Statistical Analysis 7 |
|---|--|
| Comparison groups | 50 mg Etanercept (ETN) - Induction Period v Placebo - Induction Period |
| Number of subjects included in analysis | 311 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| Statistical analysis title | WPAI-PSO Statistical Analysis 8 |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 320 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| Statistical analysis title | WPAI PSO Statistical Analysis 9 |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 326 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

Secondary: Change From Baseline in Work Productivity Loss Score of WPAI-PSO

| | |
|-----------------|--|
| End point title | Change From Baseline in Work Productivity Loss Score of WPAI-PSO |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 86 ^[63] | 199 ^[64] | 203 ^[65] | 211 ^[66] |
| Units: unit on scale | | | | |
| least squares mean (standard deviation) | | | | |
| Work Productivity Loss Score | -2.0 (± 1.80) | -13.7 (± 1.18) | -19.3 (± 1.18) | -19.5 (± 1.18) |

Notes:

[63] - All randomized participants who had baseline and at least 1 post baseline work productivity score.

[64] - All randomized participants who had baseline and at least 1 post baseline work productivity score.

[65] - All randomized participants who had baseline and at least 1 post baseline work productivity score.

[66] - All randomized participants who had baseline and at least 1 post baseline work productivity score.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | WPAI-PSO Statistical Analysis 10 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 285 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | WPAI-PSO Statistical Analysis 11 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 289 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|-----------------------------------|----------------------------------|
| Statistical analysis title | WPAI-PSO Statistical Analysis 12 |
|-----------------------------------|----------------------------------|

| | |
|---|---|
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 297 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

Secondary: Change from baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS)

| | |
|-----------------|---|
| End point title | Change from baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) |
|-----------------|---|

End point description:

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score. Missing data was imputed by last observation carried forward (LOCF).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 12

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 158 ^[67] | 336 ^[68] | 333 ^[69] | 344 ^[70] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | | | | |
| Physical Summary Score | -0.4495 (± 0.5226) | 2.5498 (± 0.3610) | 4.5726 (± 0.3628) | 3.7964 (± 0.3575) |
| Mental Summary Score | -0.0955 (± 0.5886) | 2.3221 (± 0.4065) | 2.8504 (± 0.4090) | 4.5142 (± 0.4026) |

Notes:

[67] - All randomized participants who had baseline and at least 1 post baseline SF-36 measurement.

[68] - All randomized participants who had baseline and at least 1 post baseline SF-36 measurement.

[69] - All randomized participants who had baseline and at least 1 post baseline SF-36 measurement.

[70] - All randomized participants who had baseline and at least 1 post baseline SF-36 measurement.

Statistical analyses

| | |
|----------------------------|------------------------------|
| Statistical analysis title | SF-36 Statistical Analysis 1 |
|----------------------------|------------------------------|

Statistical analysis description:

Physical Summary Score

| | |
|-------------------|--|
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
|-------------------|--|

| | |
|---|---------------|
| Number of subjects included in analysis | 494 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | SF-36 Statistical Analysis 2 |
| Statistical analysis description: Physical Summary Score | |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 491 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | SF-36 Statistical Analysis 3 |
| Statistical analysis description: Physical Summary Score | |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 502 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.01 |
| Method | ANCOVA |

| | |
|---|--|
| Statistical analysis title | SF-36 Statistical Analysis 4 |
| Statistical analysis description: Mental Summary Score | |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 494 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | SF-36 Statistical Analysis 5 |
| Statistical analysis description: Mental Summary Score | |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |

| | |
|---|---------------|
| Number of subjects included in analysis | 491 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

| | |
|---|---|
| Statistical analysis title | SF-36 Statistical Analysis 6 |
| Statistical analysis description: Mental Summary Score | |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 502 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | ANCOVA |

Secondary: Change from baseline in Patient's Global Assessment (PatGA) of Disease Severity

| | |
|-----------------|---|
| End point title | Change from baseline in Patient's Global Assessment (PatGA) of Disease Severity |
|-----------------|---|

End point description:

The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, 12 Weeks

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 164 ^[71] | 348 ^[72] | 339 ^[73] | 343 ^[74] |
| Units: units on a scale | | | | |
| least squares mean (standard error) | -0.4 (± 0.09) | -2.1 (± 0.06) | -3.0 (± 0.06) | -3.2 (± 0.06) |

Notes:

[71] - All randomized participants who had baseline and at least 1 post baseline PatGA measurement.

[72] - All randomized participants who had baseline and at least 1 post baseline PatGA measurement.

[73] - All randomized participants who had baseline and at least 1 post baseline PatGA measurement.

[74] - All randomized participants who had baseline and at least 1 post baseline PatGA measurement.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | PatGA Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 512 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | PatGA Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 503 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

| | |
|---|---|
| Statistical analysis title | PatGA Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 507 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Mixed models analysis |

Secondary: Percentage of Participants achieving Palmoplantar PASI (PPASI) of of $\geq 50\%$ (PPASI50), $\geq 75\%$ (PPASI75) or 100% (PPASI100)

| | |
|-----------------|--|
| End point title | Percentage of Participants achieving Palmoplantar PASI (PPASI) of of $\geq 50\%$ (PPASI50), $\geq 75\%$ (PPASI75) or 100% (PPASI100) |
|-----------------|--|

End point description:

The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline. Participants who did not meet clinical response criteria or have missing data will be considered non-responders.

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Week 12 | |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 55 ^[75] | 95 ^[76] | 102 ^[77] | 104 ^[78] |
| Units: percentage of participants | | | | |
| number (not applicable) | | | | |
| PPASI 50 | 43.6 | 71.6 | 85.3 | 88.5 |
| PPASI 75 | 30.9 | 61.1 | 80.4 | 79.8 |
| PPASI 100 | 25.5 | 50.5 | 69.6 | 71.2 |

Notes:

[75] - All randomized participants who had palmoplantar Ps involvement at baseline.

[76] - All randomized participants who had palmoplantar Ps involvement at baseline.

[77] - All randomized participants who had palmoplantar Ps involvement at baseline.

[78] - All randomized participants who had palmoplantar Ps involvement at baseline.

Statistical analyses

| | |
|---|--|
| Statistical analysis title | PPASI 50 Statistical Analysis 1 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 150 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PPASI 50 Statistical Analysis 2 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 157 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PPASI 50 Statistical Analysis 3 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 159 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|--|---------------------------------|
| | PPASI 75 Statistical Analysis 4 |
|--|---------------------------------|

| | |
|---|--|
| Statistical analysis title | |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 150 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PPASI 75 Statistical Analysis 5 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |
| Number of subjects included in analysis | 157 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PPASI 75 Statistical Analysis 6 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 159 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|--|
| Statistical analysis title | PPASI 100 Statistical Analysis 7 |
| Comparison groups | Placebo - Induction Period v 50 mg Etanercept (ETN) - Induction Period |
| Number of subjects included in analysis | 150 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.002 |
| Method | Cochran-Mantel-Haenszel |

| | |
|-----------------------------------|---|
| Statistical analysis title | PPASI 100 Statistical Analysis 8 |
| Comparison groups | Placebo - Induction Period v Ixe Q4W - Induction Period |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 157 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | PPASI 100 Statistical Analysis 9 |
| Comparison groups | Placebo - Induction Period v Ixe Q2W - Induction Period |
| Number of subjects included in analysis | 159 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Cochran-Mantel-Haenszel |

Secondary: Percentage of participants with Anti-Ixekizumab Antibodies

| | |
|------------------------|--|
| End point title | Percentage of participants with Anti-Ixekizumab Antibodies |
| End point description: | Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants * 100%. |
| End point type | Secondary |
| End point timeframe: | Baseline to Week 12 |

| End point values | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|-----------------------------------|----------------------------|---|----------------------------|----------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 165 ^[79] | 347 ^[80] | 340 ^[81] | 346 ^[82] |
| Units: Percentage of Participants | | | | |
| number (not applicable) | 0 | 2.9 | 14.1 | 10.4 |

Notes:

[79] - All randomized participants who received at least 1 dose of study treatment and had evaluable data.

[80] - All randomized participants who received at least 1 dose of study treatment and had evaluable data.

[81] - All randomized participants who received at least 1 dose of study treatment and had evaluable data.

[82] - All randomized participants who received at least 1 dose of study treatment and had evaluable data.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Induction, Maintenance Dosing, Long Term Extension and Follow-Up Periods

Adverse event reporting additional description:

I1F-MC-RHBA

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 22.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|----------------------------|
| Reporting group title | Placebo - Induction period |
|-----------------------|----------------------------|

Reporting group description: -

| | |
|-----------------------|------------------------------|
| Reporting group title | 50 mg ETN - Induction Period |
|-----------------------|------------------------------|

Reporting group description: -

| | |
|-----------------------|----------------------------|
| Reporting group title | Ixe Q4W - Induction period |
|-----------------------|----------------------------|

Reporting group description: -

| | |
|-----------------------|----------------------------|
| Reporting group title | Ixe Q2W - Induction period |
|-----------------------|----------------------------|

Reporting group description: -

| | |
|-----------------------|---|
| Reporting group title | Ixe/Placebo - Maintenance Period Primary Population |
|-----------------------|---|

Reporting group description: -

| | |
|-----------------------|---|
| Reporting group title | Ixe/Ixe Q4W - Maintenance Period Primary Population |
|-----------------------|---|

Reporting group description: -

| | |
|-----------------------|--|
| Reporting group title | Ixe/Ixe Q12W - Maintenance Period Primary Population |
|-----------------------|--|

Reporting group description: -

| | |
|-----------------------|--|
| Reporting group title | Placebo Resp/Placebo - Maintenance Period Secondary Population |
|-----------------------|--|

Reporting group description: -

| | |
|-----------------------|--|
| Reporting group title | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop |
|-----------------------|--|

Reporting group description: -

| | |
|-----------------------|---|
| Reporting group title | ETNResp/Placebo - Maintenance Period Secondary Population |
|-----------------------|---|

Reporting group description: -

| | |
|-----------------------|---|
| Reporting group title | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Population |
|-----------------------|---|

Reporting group description: -

| | |
|-----------------------|--|
| Reporting group title | Ixe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary Pop |
|-----------------------|--|

Reporting group description: -

| | |
|-----------------------|--|
| Reporting group title | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary Pop |
|-----------------------|--|

Reporting group description: -

| | |
|-----------------------|--|
| Reporting group title | Ixe Q4W - Maintenance Relapse Population |
|-----------------------|--|

Reporting group description: -

| | |
|-----------------------|------------------------------------|
| Reporting group title | Placebo Long-Term Extension Period |
|-----------------------|------------------------------------|

Reporting group description: -

| | |
|-----------------------|--------------------------------|
| Reporting group title | Ixe Long-Term Extension Period |
|-----------------------|--------------------------------|

Reporting group description: -

| | |
|-----------------------|--------------------------------------|
| Reporting group title | Total Ixe Long-Term Extension Period |
|-----------------------|--------------------------------------|

Reporting group description: -

| | |
|-----------------------|----------------------------------|
| Reporting group title | Placebo Post-Treatment Follow-Up |
|-----------------------|----------------------------------|

Reporting group description: -

| | |
|-----------------------|------------------------------|
| Reporting group title | ETN Post-Treatment Follow-Up |
|-----------------------|------------------------------|

Reporting group description: -

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Ixe Q12W Post-Treatment Follow-Up |
|-----------------------|-----------------------------------|

Reporting group description: -

| | |
|-----------------------|----------------------------------|
| Reporting group title | Ixe Q4W Post-Treatment Follow-Up |
|-----------------------|----------------------------------|

Reporting group description: -

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Ixe Q12W Post-Treatment Follow-Up |
|-----------------------|-----------------------------------|

Reporting group description: -

| Serious adverse events | Placebo - Induction period | 50 mg ETN - Induction Period | Ixe Q4W - Induction period |
|---|----------------------------|------------------------------|----------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 3 / 167 (1.80%) | 8 / 357 (2.24%) | 8 / 347 (2.31%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| invasive ductal breast carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant melanoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pituitary tumour benign | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| prostate cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 0 / 119 (0.00%) | 0 / 235 (0.00%) | 0 / 244 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyogenic granuloma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour embolism alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[2] | 0 / 48 (0.00%) | 0 / 122 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders aortic aneurysm alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic dilatation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| circulatory collapse | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant hypertension | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral arterial occlusive disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| peripheral artery stenosis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| coronary revascularisation alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gallbladder operation alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrectomy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine dilation and curettage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 48 (0.00%) | 0 / 122 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 0 / 48 (0.00%) | 0 / 122 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| imminent abortion | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 48 (0.00%) | 0 / 122 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 0 / 119 (0.00%) | 0 / 235 (0.00%) | 0 / 244 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 0 / 119 (0.00%) | 0 / 235 (0.00%) | 0 / 244 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 0 / 119 (0.00%) | 0 / 235 (0.00%) | 0 / 244 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 167 (0.60%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sleep apnoea syndrome | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillar hypertrophy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| anxiety | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| depression | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psychotic disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| schizophrenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| suicide attempt | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| electrocardiogram abnormal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| mycobacterium tuberculosis complex test positive | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| weight increased | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical vertebral fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hand fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| head injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint dislocation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ligament rupture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| maternal exposure during pregnancy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed ^[9] | 0 / 48 (0.00%) | 0 / 122 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| meniscus injury alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple fractures alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| post procedural haemorrhage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound complication alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rib fracture alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| road traffic accident alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| skin laceration alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] | 0 / 119 (0.00%) | 0 / 235 (0.00%) | 0 / 244 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders acute myocardial infarction | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| angina unstable | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic valve disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac arrest | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial infarction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| right ventricular failure alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus node dysfunction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders carpal tunnel syndrome alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| multiple sclerosis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myelopathy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sciatica alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| anaemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 167 (0.60%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| vertigo alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| optic ischaemic neuropathy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal discomfort alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypertrophic anal papilla | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| inguinal hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lumbar hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| noninfective sialoadenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal achalasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stone | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary colic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 167 (0.60%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| stress urinary incontinence alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc protrusion alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 48 (0.00%) | 0 / 122 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis staphylococcal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| clostridium difficile infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| eczema infected | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| necrotising fasciitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| otitis media chronic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonsillar abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pilonidal cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| pneumonia pseudomonal alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal abscess alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhinitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed ^[12] | 0 / 48 (0.00%) | 0 / 122 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urinary tract infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| wound infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obesity alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 0 / 347 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 167 (0.00%) | 0 / 357 (0.00%) | 1 / 347 (0.29%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Ixe Q2W - Induction period | Ixe/Placebo - Maintenance Period Primary Population | Ixe/Ixe Q4W - Maintenance Period Primary Population |
|---|----------------------------|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 5 / 350 (1.43%) | 8 / 176 (4.55%) | 12 / 187 (6.42%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| invasive ductal breast carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant melanoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pituitary tumour benign alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| prostate cancer alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 0 / 221 (0.00%) | 0 / 110 (0.00%) | 1 / 131 (0.76%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyogenic granuloma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| renal cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour embolism alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[2] | 0 / 129 (0.00%) | 1 / 66 (1.52%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| aortic aneurysm alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic dilatation alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| circulatory collapse | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant hypertension | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral arterial occlusive disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Surgical and medical procedures | | | |
| coronary revascularisation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gallbladder operation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrectomy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine dilation and curettage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 129 (0.00%) | 0 / 66 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 0 / 129 (0.00%) | 0 / 66 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| imminent abortion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 129 (0.00%) | 0 / 66 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 0 / 221 (0.00%) | 0 / 110 (0.00%) | 0 / 131 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 0 / 221 (0.00%) | 0 / 110 (0.00%) | 0 / 131 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 0 / 221 (0.00%) | 0 / 110 (0.00%) | 0 / 131 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 350 (0.29%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sleep apnoea syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillar hypertrophy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| anxiety alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| depression alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psychotic disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| schizophrenia alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| suicide attempt alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 350 (0.29%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| electrocardiogram abnormal alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| weight increased alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical vertebral fracture alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| hand fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| head injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint dislocation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ligament rupture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| maternal exposure during pregnancy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[9] | 0 / 129 (0.00%) | 0 / 66 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| meniscus injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple fractures alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| post procedural haemorrhage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound complication alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rib fracture alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| road traffic accident alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| skin laceration alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] | 0 / 221 (0.00%) | 0 / 110 (0.00%) | 0 / 131 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| angina unstable | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic valve disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac arrest | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial infarction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| right ventricular failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus node dysfunction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| carpal tunnel syndrome | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple sclerosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| myelopathy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sciatica alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| anaemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| vertigo alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| optic ischaemic neuropathy | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 350 (0.29%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| gastritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 350 (0.29%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypertrophic anal papilla | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| inguinal hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lumbar hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| noninfective sialoadenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal achalasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 350 (0.29%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stone alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary colic alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| stress urinary incontinence | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc protrusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 350 (0.29%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 129 (0.00%) | 0 / 66 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| cellulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis staphylococcal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| clostridium difficile infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 1 / 176 (0.57%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| eczema infected | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| necrotising fasciitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| otitis media chronic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonsillar abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pilonidal cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia pseudomonal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhinitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 1 / 187 (0.53%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[12] | 0 / 129 (0.00%) | 0 / 66 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| wound infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 350 (0.29%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obesity alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 350 (0.00%) | 0 / 176 (0.00%) | 0 / 187 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------|--|---|--|
| Serious adverse events | Ixe/Ixe Q12W - Maintenance Period Primary Population | Placebo Resp/Placebo - Maintenance Period | Placebo NonResp/Ixe Q4W - Maintenance Period |
|-------------------------------|--|---|--|

| | | Secondary Population | Secondary Pop |
|---|------------------|----------------------|------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 14 / 181 (7.73%) | 0 / 3 (0.00%) | 13 / 155 (8.39%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| invasive ductal breast carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant melanoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pituitary tumour benign | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| prostate cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 1 / 120 (0.83%) | 0 / 1 (0.00%) | 0 / 112 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyogenic granuloma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal cell carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|---------------|-----------------|
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour embolism alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[2] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 0 / 43 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| aortic aneurysm alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic dilatation alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic stenosis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| circulatory collapse | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant hypertension | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral arterial occlusive disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| coronary revascularisation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gallbladder operation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrectomy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine dilation and curettage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 0 / 43 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 0 / 43 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| imminent abortion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 1 / 43 (2.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 0 / 120 (0.00%) | 0 / 1 (0.00%) | 0 / 112 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 0 / 120 (0.00%) | 0 / 1 (0.00%) | 0 / 112 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 0 / 120 (0.00%) | 0 / 1 (0.00%) | 0 / 112 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sleep apnoea syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillar hypertrophy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| anxiety alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| depression alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psychotic disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| schizophrenia alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| suicide attempt | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| electrocardiogram abnormal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| mycobacterium tuberculosis complex test positive | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| weight increased | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical vertebral fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|---------------|-----------------|
| hand fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| head injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint dislocation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ligament rupture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| maternal exposure during pregnancy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[9] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 0 / 43 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| meniscus injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple fractures alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| post procedural haemorrhage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound complication alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rib fracture alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| road traffic accident alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| skin laceration alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|---------------|-----------------|
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] | 0 / 120 (0.00%) | 0 / 1 (0.00%) | 0 / 112 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| angina unstable | | | |

| | | | |
|--|-----------------|---------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic valve disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac arrest | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial infarction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| right ventricular failure alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus node dysfunction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| carpal tunnel syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple sclerosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|---------------|-----------------|
| myelopathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sciatica alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders vertigo alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders optic ischaemic neuropathy | | | |

| | | | |
|--|-----------------|---------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|---------------|-----------------|
| gastritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypertrophic anal papilla | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| inguinal hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lumbar hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| noninfective sialoadenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal achalasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stone alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary colic alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| stress urinary incontinence | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc protrusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 0 / 43 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|---------------|-----------------|
| cellulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis staphylococcal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| clostridium difficile infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| eczema infected | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|---------------|-----------------|
| necrotising fasciitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| otitis media chronic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonsillar abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pilonidal cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia pseudomonal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|---------------|-----------------|
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhinitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[12] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 0 / 43 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|---------------|-----------------|
| urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| wound infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obesity alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 0 / 155 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | ETNResp/Placebo - Maintenance Period Secondary | ETN NonResp/Ixe Q4W - Maintenance Period Secondary | Ixe Q4W NonResp/Ixe Q4W - Maintenance Period |
|-------------------------------|--|--|--|
|-------------------------------|--|--|--|

| | Population | Population | Secondary Pop |
|---|-----------------|-----------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 132 (1.52%) | 9 / 200 (4.50%) | 4 / 75 (5.33%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| invasive ductal breast carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant melanoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pituitary tumour benign | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| prostate cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 0 / 89 (0.00%) | 0 / 126 (0.00%) | 0 / 53 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyogenic granuloma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal cell carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|----------------|
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour embolism alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[2] | 0 / 43 (0.00%) | 0 / 74 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| aortic aneurysm alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic dilatation alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic stenosis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| circulatory collapse | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant hypertension | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral arterial occlusive disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| coronary revascularisation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gallbladder operation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrectomy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine dilation and curettage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 43 (0.00%) | 0 / 74 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 0 / 43 (0.00%) | 0 / 74 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| imminent abortion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 43 (0.00%) | 0 / 74 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 0 / 89 (0.00%) | 0 / 126 (0.00%) | 0 / 53 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 0 / 89 (0.00%) | 0 / 126 (0.00%) | 0 / 53 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 0 / 89 (0.00%) | 0 / 126 (0.00%) | 0 / 53 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sleep apnoea syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillar hypertrophy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| anxiety alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| depression alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psychotic disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| schizophrenia alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| suicide attempt alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| electrocardiogram abnormal alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| weight increased alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical vertebral fracture alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|----------------|
| hand fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| head injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint dislocation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ligament rupture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| maternal exposure during pregnancy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[9] | 0 / 43 (0.00%) | 0 / 74 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| meniscus injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple fractures alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| post procedural haemorrhage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound complication alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rib fracture alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| road traffic accident alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| skin laceration alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|----------------|
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] | 0 / 89 (0.00%) | 0 / 126 (0.00%) | 0 / 53 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| angina unstable | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic valve disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac arrest | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial infarction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| right ventricular failure alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus node dysfunction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| carpal tunnel syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 1 / 75 (1.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple sclerosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|----------------|
| myelopathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sciatica alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders vertigo alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders optic ischaemic neuropathy | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|----------------|
| gastritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypertrophic anal papilla | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| inguinal hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lumbar hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| noninfective sialoadenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 1 / 75 (1.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal achalasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stone alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary colic alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 132 (0.76%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| stress urinary incontinence | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc protrusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 1 / 75 (1.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 43 (0.00%) | 0 / 74 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|----------------|
| cellulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis staphylococcal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 132 (0.76%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| clostridium difficile infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| eczema infected | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|----------------|
| necrotising fasciitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| otitis media chronic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonsillar abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pilonidal cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 1 / 75 (1.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia pseudomonal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhinitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[12] | 0 / 43 (0.00%) | 0 / 74 (0.00%) | 0 / 22 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|----------------|
| urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| wound infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obesity alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period | Ixe Q4W - Maintenance Relapse Population | Placebo Long-Term Extension Period |
|-------------------------------|--|--|---------------------------------------|
|-------------------------------|--|--|---------------------------------------|

| | Secondary Pop | | |
|---|----------------|------------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | 14 / 368 (3.80%) | 1 / 26 (3.85%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| invasive ductal breast carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant melanoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pituitary tumour benign | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| prostate cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 0 / 30 (0.00%) | 0 / 239 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyogenic granuloma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal cell carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|-----------------|----------------|
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour embolism alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[2] | 0 / 19 (0.00%) | 0 / 129 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| aortic aneurysm alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic dilatation alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic stenosis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| circulatory collapse alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deep vein thrombosis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant hypertension alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral arterial occlusive disease alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral artery stenosis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures coronary revascularisation alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gallbladder operation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrectomy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine dilation and curettage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 19 (0.00%) | 0 / 129 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 0 / 19 (0.00%) | 1 / 129 (0.78%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| imminent abortion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 19 (0.00%) | 0 / 129 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 0 / 30 (0.00%) | 0 / 239 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 0 / 30 (0.00%) | 0 / 239 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 0 / 30 (0.00%) | 0 / 239 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 1 / 26 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sleep apnoea syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillar hypertrophy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| anxiety alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| depression alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psychotic disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| schizophrenia alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| suicide attempt alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| electrocardiogram abnormal alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| weight increased alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical vertebral fracture alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|-----------------|----------------|
| hand fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| head injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint dislocation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ligament rupture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| maternal exposure during pregnancy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[9] | 0 / 19 (0.00%) | 0 / 129 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| meniscus injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple fractures alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| post procedural haemorrhage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound complication alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rib fracture alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| road traffic accident alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| skin laceration alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|-----------------|----------------|
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] | 0 / 30 (0.00%) | 0 / 239 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| angina unstable | | | |

| | | | |
|--|----------------|-----------------|----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic valve disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac arrest | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial infarction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| right ventricular failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus node dysfunction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| carpal tunnel syndrome | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 1 / 26 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple sclerosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|-----------------|----------------|
| myelopathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sciatica alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders vertigo alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders optic ischaemic neuropathy | | | |

| | | | |
|--|----------------|-----------------|----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 1 / 26 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|-----------------|----------------|
| gastritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypertrophic anal papilla | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| inguinal hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lumbar hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| noninfective sialoadenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal achalasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stone alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary colic alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| stress urinary incontinence | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc protrusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 19 (0.00%) | 1 / 129 (0.78%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|-----------------|----------------|
| cellulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis staphylococcal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| clostridium difficile infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| eczema infected | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|-----------------|----------------|
| necrotising fasciitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| otitis media chronic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonsillar abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pilonidal cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia pseudomonal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhinitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[12] | 0 / 19 (0.00%) | 0 / 129 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|----------------|-----------------|----------------|
| urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| wound infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obesity alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 49 (0.00%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Ixe Long-Term Extension Period | Total Ixe Long-Term Extension Period | Placebo Post- Treatment Follow-Up |
|------------------------------------|-----------------------------------|---|--------------------------------------|
| Total subjects affected by serious | | | |

| | | | |
|---|--------------------|---------------------|----------------|
| adverse events | | | |
| subjects affected / exposed | 107 / 979 (10.93%) | 107 / 1002 (10.68%) | 1 / 16 (6.25%) |
| number of deaths (all causes) | 4 | 4 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| invasive ductal breast carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant melanoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pituitary tumour benign | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| prostate cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 3 / 666 (0.45%) | 3 / 678 (0.44%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyogenic granuloma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal cell carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|------------------|----------------|
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour embolism alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[2] | 0 / 313 (0.00%) | 0 / 324 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| aortic aneurysm alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic dilatation alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic stenosis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| circulatory collapse | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant hypertension | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral arterial occlusive disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| coronary revascularisation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gallbladder operation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrectomy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine dilation and curettage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 313 (0.00%) | 0 / 324 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 1 / 313 (0.32%) | 1 / 324 (0.31%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| imminent abortion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 313 (0.00%) | 0 / 324 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 1 / 666 (0.15%) | 1 / 678 (0.15%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 2 / 666 (0.30%) | 2 / 678 (0.29%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 1 / 666 (0.15%) | 1 / 678 (0.15%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|------------------|----------------|
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sleep apnoea syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillar hypertrophy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| anxiety alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| depression alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psychotic disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| schizophrenia alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| suicide attempt alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| electrocardiogram abnormal alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| weight increased alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical vertebral fracture alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 3 / 979 (0.31%) | 3 / 1002 (0.30%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|------------------|----------------|
| hand fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| head injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint dislocation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ligament rupture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| maternal exposure during pregnancy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[9] | 1 / 313 (0.32%) | 1 / 324 (0.31%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| meniscus injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple fractures alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| post procedural haemorrhage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound complication alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rib fracture alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| road traffic accident alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| skin laceration alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|------------------|----------------|
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] | 1 / 666 (0.15%) | 1 / 678 (0.15%) | 0 / 10 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 3 / 979 (0.31%) | 3 / 1002 (0.30%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| angina unstable | | | |

| | | | |
|--|-----------------|------------------|----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic valve disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac arrest | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| coronary artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial infarction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|------------------|----------------|
| subjects affected / exposed | 3 / 979 (0.31%) | 3 / 1002 (0.30%) | 1 / 16 (6.25%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| right ventricular failure alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus node dysfunction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| carpal tunnel syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 3 / 979 (0.31%) | 3 / 1002 (0.30%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple sclerosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|------------------|----------------|
| myelopathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sciatica alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders vertigo alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders optic ischaemic neuropathy | | | |

| | | | |
|--|-----------------|------------------|----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|------------------|----------------|
| gastritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypertrophic anal papilla | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| inguinal hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lumbar hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| noninfective sialoadenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal achalasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stone alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary colic alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| stress urinary incontinence | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc protrusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 4 / 979 (0.41%) | 4 / 1002 (0.40%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 5 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 313 (0.00%) | 0 / 324 (0.00%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|------------------|----------------|
| cellulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 6 / 979 (0.61%) | 6 / 1002 (0.60%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 6 / 8 | 6 / 8 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis staphylococcal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| clostridium difficile infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| eczema infected | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 3 / 979 (0.31%) | 3 / 1002 (0.30%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 2 / 3 | 2 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|------------------|----------------|
| necrotising fasciitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 3 / 3 | 3 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| otitis media chronic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonsillar abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pilonidal cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 5 / 979 (0.51%) | 5 / 1002 (0.50%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 4 / 5 | 4 / 5 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia pseudomonal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|------------------|----------------|
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 1 / 2 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhinitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 979 (0.20%) | 2 / 1002 (0.20%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[12] | 1 / 313 (0.32%) | 1 / 324 (0.31%) | 0 / 6 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|------------------|----------------|
| urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| wound infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obesity alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 1 / 979 (0.10%) | 1 / 1002 (0.10%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 979 (0.00%) | 0 / 1002 (0.00%) | 0 / 16 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | ETN Post-Treatment Follow-Up | Ixe Q12W Post- Treatment Follow-Up | Ixe Q4W Post- Treatment Follow-Up |
|------------------------------------|---------------------------------|---------------------------------------|--------------------------------------|
| Total subjects affected by serious | | | |

| | | | |
|---|---------------|-----------------|------------------|
| adverse events | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 3 / 248 (1.21%) | 12 / 656 (1.83%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| invasive ductal breast carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant melanoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pituitary tumour benign | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| prostate cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 0 / 5 (0.00%) | 0 / 170 (0.00%) | 0 / 453 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyogenic granuloma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal cell carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|-----------------|-----------------|
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour embolism alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[2] | 0 / 1 (0.00%) | 0 / 78 (0.00%) | 0 / 203 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| aortic aneurysm alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic dilatation alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic stenosis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| circulatory collapse | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| malignant hypertension | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral arterial occlusive disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peripheral artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| coronary revascularisation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gallbladder operation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrectomy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine dilation and curettage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 1 (0.00%) | 1 / 78 (1.28%) | 0 / 203 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 0 / 1 (0.00%) | 0 / 78 (0.00%) | 1 / 203 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| imminent abortion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 1 (0.00%) | 0 / 78 (0.00%) | 0 / 203 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 0 / 5 (0.00%) | 0 / 170 (0.00%) | 0 / 453 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 0 / 5 (0.00%) | 0 / 170 (0.00%) | 0 / 453 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 0 / 5 (0.00%) | 0 / 170 (0.00%) | 0 / 453 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sleep apnoea syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillar hypertrophy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| anxiety alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| depression alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psychotic disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| schizophrenia alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| suicide attempt alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| electrocardiogram abnormal alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| weight increased alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical vertebral fracture alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|---------------|-----------------|-----------------|
| hand fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| head injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint dislocation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| joint injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ligament rupture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| maternal exposure during pregnancy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[9] | 0 / 1 (0.00%) | 0 / 78 (0.00%) | 0 / 203 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| meniscus injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple fractures alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| post procedural haemorrhage alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound complication alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rib fracture alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| road traffic accident alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| skin laceration alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|-----------------|-----------------|
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] | 0 / 5 (0.00%) | 0 / 170 (0.00%) | 0 / 453 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| angina unstable | | | |

| | | | |
|--|---------------|-----------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| aortic valve disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac arrest | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial infarction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 248 (0.40%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| right ventricular failure alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sinus node dysfunction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| carpal tunnel syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multiple sclerosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---------------|-----------------|-----------------|
| myelopathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sciatica alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders vertigo alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders optic ischaemic neuropathy | | | |

| | | | |
|--|---------------|-----------------|-----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|---------------|-----------------|-----------------|
| gastritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypertrophic anal papilla | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| inguinal hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lumbar hernia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| noninfective sialoadenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal achalasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stone alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary colic alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 3 / 656 (0.46%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 2 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| stress urinary incontinence | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intervertebral disc protrusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 1 (0.00%) | 0 / 78 (0.00%) | 0 / 203 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|---------------|-----------------|-----------------|
| cellulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 248 (0.40%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cellulitis staphylococcal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| clostridium difficile infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diverticulitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| eczema infected | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|---------------|-----------------|-----------------|
| necrotising fasciitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophageal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| otitis media chronic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonsillar abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pilonidal cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia pseudomonal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| postoperative wound infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhinitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tonsillitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[12] | 0 / 1 (0.00%) | 0 / 78 (0.00%) | 0 / 203 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|---------------|-----------------|-----------------|
| urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| wound infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obesity alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|------------------------------------|-----------------------------------|--|--|
| Serious adverse events | Ixe Q12W Post-Treatment Follow-Up | | |
| Total subjects affected by serious | | | |

| | | | |
|---|----------------|--|--|
| adverse events | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| breast cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| breast neoplasm | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| cholesteatoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| colon adenoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| follicular thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| invasive ductal breast carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| malignant melanoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pituitary tumour benign | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| prostate cancer | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[1] | 0 / 14 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pyogenic granuloma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| renal cell carcinoma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|--|----------------|--|--|
| small intestine adenocarcinoma alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| transitional cell carcinoma alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| tumour embolism alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| uterine leiomyoma alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[2] | 0 / 10 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| aortic aneurysm alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| aortic dilatation alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| aortic stenosis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| circulatory collapse | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| malignant hypertension | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| peripheral arterial occlusive disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| peripheral artery stenosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Surgical and medical procedures | | | |
| coronary revascularisation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| gallbladder operation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| gastrectomy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| uterine dilation and curettage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[3] | 0 / 10 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[4] | 0 / 10 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| imminent abortion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[5] | 0 / 10 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| death | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| injection site reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| polyp | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pyrexia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| anaphylactic reaction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| hypersensitivity | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reproductive system and breast disorders | | | |
| acquired hydrocele | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[6] | 0 / 14 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| benign prostatic hyperplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[7] | 0 / 14 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| penile dysplasia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[8] | 0 / 14 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| acute respiratory failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| asthma | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| chronic obstructive pulmonary disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| sinus disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| sleep apnoea syndrome alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| tonsillar hypertrophy alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| anxiety alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| depression alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| psychotic disorder alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| schizophrenia alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| suicide attempt | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| electrocardiogram abnormal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| mycobacterium tuberculosis complex test positive | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| weight increased | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| alcohol poisoning | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| cervical vertebral fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| concussion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| exposure via father | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| facial bones fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| fall | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| femur fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|--|----------------|--|--|--|
| hand fracture | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| head injury | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| joint dislocation | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| joint injury | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| ligament rupture | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| maternal exposure during pregnancy | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed ^[9] | 0 / 10 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| meniscus injury | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| multiple fractures | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| post procedural haemorrhage | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| postoperative wound complication | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| rib fracture | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| road traffic accident | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| skin laceration | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|--|--|--|--|
| sternal fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| tendon rupture alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| thoracic vertebral fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| tibia fracture alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| Congenital, familial and genetic disorders frenulum breve alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[10] occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 14 (0.00%) 0 / 0 0 / 0 | | |
| Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all angina unstable | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |

| | | | | |
|--|----------------|--|--|--|
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| aortic valve disease | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| atrial fibrillation | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| cardiac arrest | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| coronary artery disease | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| coronary artery stenosis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| myocardial infarction | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| myocardial ischaemia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pericardial effusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| right ventricular failure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| sinus node dysfunction | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| carpal tunnel syndrome | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| cerebrovascular accident | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| cognitive disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| generalised tonic-clonic seizure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| loss of consciousness | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| multiple sclerosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|--|----------------------------------|--|--|
| myelopathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| sciatica alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| syncope alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| transient ischaemic attack alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| Ear and labyrinth disorders vertigo alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all | 0 / 24 (0.00%) 0 / 0 0 / 0 | | |
| Eye disorders optic ischaemic neuropathy | | | |

| | | | |
|--|----------------|--|--|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| photophobia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| anal fissure | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| anal fistula | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| colitis ulcerative | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| crohn's disease | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| diverticular perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| duodenitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| gastric perforation | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|--|----------------|--|--|--|
| gastritis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| hypertrophic anal papilla | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| inguinal hernia | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| lumbar hernia | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| noninfective sialoadenitis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| oesophageal achalasia | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| oesophagitis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| small intestinal obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| bile duct obstruction alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| bile duct stone alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| biliary colic alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| cholangitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| cholecystitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| cholestasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| hepatic mass | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| angioedema | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| dermatitis allergic | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| erythrodermic psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| pustular psoriasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| rash | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| urticaria | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| nephrolithiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| stress urinary incontinence | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| arthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| bursitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| intervertebral disc disorder | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| intervertebral disc protrusion | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| spinal pain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| synovial cyst | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| synovitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| abscess intestinal | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| abscess limb | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| abscess oral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| appendicitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| bartholin's abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[11] | 0 / 10 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| biliary sepsis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| bursitis infective | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|--|----------------|--|--|--|
| cellulitis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| cellulitis staphylococcal | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| cholecystitis infective | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| clostridium difficile infection | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| diverticulitis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| ear infection | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| eczema infected | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| encephalitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| erysipelas | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| gastroenteritis viral | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| groin abscess | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| haematoma infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| infectious mononucleosis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|--|----------------|--|--|--|
| necrotising fasciitis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| oesophageal candidiasis | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| otitis media chronic | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| peritonsillar abscess | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| pilonidal cyst | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| pneumonia | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| pneumonia pseudomonal | | | | |
| alternative dictionary used: MedDRA 22.0 | | | | |

| | | | |
|--|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| postoperative wound infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| renal abscess alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| rhinitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| sepsis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| tonsillitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| tubo-ovarian abscess alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[12] | 0 / 10 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|--|----------------|--|--|
| urinary tract infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| wound infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| hyponatraemia alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| obesity alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| type 2 diabetes mellitus alternative dictionary used: MedDRA 22.0 subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[11] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[12] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo - Induction period | 50 mg ETN - Induction Period | Ixe Q4W - Induction period |
|---|------------------------------|------------------------------|------------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 48 / 167 (28.74%) | 141 / 357 (39.50%) | 116 / 347 (33.43%) |
| Investigations mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 167 (0.00%) 0 | 0 / 357 (0.00%) 0 | 0 / 347 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--|--|---|---|
| <p>muscle strain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 167 (0.60%)</p> <p>1</p> | <p>0 / 357 (0.00%)</p> <p>0</p> | <p>2 / 347 (0.58%)</p> <p>2</p> |
| <p>Nervous system disorders</p> <p>headache</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>vocal cord paresis</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>2 / 167 (1.20%)</p> <p>3</p> <p>0 / 167 (0.00%)</p> <p>0</p> | <p>21 / 357 (5.88%)</p> <p>22</p> <p>0 / 357 (0.00%)</p> <p>0</p> | <p>17 / 347 (4.90%)</p> <p>21</p> <p>0 / 347 (0.00%)</p> <p>0</p> |
| <p>General disorders and administration site conditions</p> <p>asthenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site erythema</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site reaction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 167 (0.00%)</p> <p>0</p> <p>2 / 167 (1.20%)</p> <p>2</p> <p>2 / 167 (1.20%)</p> <p>33</p> <p>1 / 167 (0.60%)</p> <p>1</p> | <p>2 / 357 (0.56%)</p> <p>2</p> <p>18 / 357 (5.04%)</p> <p>64</p> <p>4 / 357 (1.12%)</p> <p>5</p> <p>38 / 357 (10.64%)</p> <p>192</p> | <p>3 / 347 (0.86%)</p> <p>3</p> <p>9 / 347 (2.59%)</p> <p>10</p> <p>5 / 347 (1.44%)</p> <p>33</p> <p>19 / 347 (5.48%)</p> <p>30</p> |
| <p>Reproductive system and breast disorders</p> <p>amenorrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> | | | |

| | | | |
|--|----------------------|-----------------------|-----------------------|
| subjects affected / exposed ^[13] occurrences (all) | 0 / 48 (0.00%) 0 | 0 / 122 (0.00%) 0 | 0 / 103 (0.00%) 0 |
| Gastrointestinal disorders diarrhoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 167 (0.60%) 1 | 2 / 357 (0.56%) 2 | 4 / 347 (1.15%) 4 |
| nausea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 167 (1.80%) 6 | 1 / 357 (0.28%) 2 | 5 / 347 (1.44%) 6 |
| Respiratory, thoracic and mediastinal disorders oropharyngeal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 167 (0.00%) 0 | 5 / 357 (1.40%) 7 | 5 / 347 (1.44%) 5 |
| Skin and subcutaneous tissue disorders psoriasis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 5 / 167 (2.99%) 5 | 7 / 357 (1.96%) 7 | 6 / 347 (1.73%) 6 |
| Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 5 / 167 (2.99%) 6 | 9 / 357 (2.52%) 10 | 8 / 347 (2.31%) 10 |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 167 (0.00%) 0 | 0 / 357 (0.00%) 0 | 0 / 347 (0.00%) 0 |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 167 (1.80%) 3 | 5 / 357 (1.40%) 7 | 2 / 347 (0.58%) 2 |
| musculoskeletal chest pain | | | |

| | | | |
|---|-------------------|-------------------|------------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 1 / 357 (0.28%) | 0 / 347 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 167 (1.20%) | 1 / 357 (0.28%) | 2 / 347 (0.58%) |
| occurrences (all) | 2 | 1 | 2 |
| Infections and infestations | | | |
| bronchitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 3 / 167 (1.80%) | 5 / 357 (1.40%) | 4 / 347 (1.15%) |
| occurrences (all) | 3 | 5 | 4 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 167 (0.60%) | 0 / 357 (0.00%) | 2 / 347 (0.58%) |
| occurrences (all) | 1 | 0 | 2 |
| nasopharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 17 / 167 (10.18%) | 37 / 357 (10.36%) | 28 / 347 (8.07%) |
| occurrences (all) | 21 | 41 | 40 |
| pharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 5 / 357 (1.40%) | 5 / 347 (1.44%) |
| occurrences (all) | 0 | 5 | 5 |
| sinusitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 167 (0.00%) | 4 / 357 (1.12%) | 6 / 347 (1.73%) |
| occurrences (all) | 0 | 4 | 6 |
| upper respiratory tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 7 / 167 (4.19%) | 27 / 357 (7.56%) | 16 / 347 (4.61%) |
| occurrences (all) | 8 | 27 | 19 |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 2 / 167 (1.20%) 2 | 2 / 357 (0.56%) 2 | 7 / 347 (2.02%) 7 |
| vulvovaginal candidiasis alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[14] occurrences (all) | 0 / 48 (0.00%) 0 | 1 / 122 (0.82%) 1 | 0 / 103 (0.00%) 0 |

| Non-serious adverse events | Ixe Q2W - Induction period | Ixe/Placebo - Maintenance Period Primary Population | Ixe/Ixe Q4W - Maintenance Period Primary Population |
|--|--|---|---|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 140 / 350 (40.00%) | 56 / 176 (31.82%) | 100 / 187 (53.48%) |
| Investigations mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 350 (0.00%) 0 | 0 / 176 (0.00%) 0 | 3 / 187 (1.60%) 3 |
| Injury, poisoning and procedural complications muscle strain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 350 (0.86%) 3 | 1 / 176 (0.57%) 1 | 2 / 187 (1.07%) 2 |
| Nervous system disorders headache alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) vocal cord paresis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 17 / 350 (4.86%) 23 0 / 350 (0.00%) 0 | 7 / 176 (3.98%) 9 0 / 176 (0.00%) 0 | 12 / 187 (6.42%) 14 0 / 187 (0.00%) 0 |
| General disorders and administration site conditions asthenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 350 (0.00%) 0 | 0 / 176 (0.00%) 0 | 1 / 187 (0.53%) 1 |

| | | | |
|--|---|---|---|
| <p>injection site erythema</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>12 / 350 (3.43%)</p> <p>20</p> | <p>2 / 176 (1.14%)</p> <p>3</p> | <p>3 / 187 (1.60%)</p> <p>6</p> |
| <p>injection site pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>13 / 350 (3.71%)</p> <p>79</p> | <p>4 / 176 (2.27%)</p> <p>22</p> | <p>1 / 187 (0.53%)</p> <p>3</p> |
| <p>injection site reaction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>40 / 350 (11.43%)</p> <p>76</p> | <p>0 / 176 (0.00%)</p> <p>0</p> | <p>15 / 187 (8.02%)</p> <p>69</p> |
| <p>Reproductive system and breast disorders</p> <p>amenorrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[13]</p> <p>occurrences (all)</p> | <p>0 / 129 (0.00%)</p> <p>0</p> | <p>0 / 66 (0.00%)</p> <p>0</p> | <p>1 / 56 (1.79%)</p> <p>1</p> |
| <p>Gastrointestinal disorders</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nausea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>6 / 350 (1.71%)</p> <p>7</p> <p>7 / 350 (2.00%)</p> <p>7</p> | <p>4 / 176 (2.27%)</p> <p>5</p> <p>2 / 176 (1.14%)</p> <p>3</p> | <p>4 / 187 (2.14%)</p> <p>4</p> <p>2 / 187 (1.07%)</p> <p>2</p> |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>5 / 350 (1.43%)</p> <p>5</p> | <p>1 / 176 (0.57%)</p> <p>2</p> | <p>3 / 187 (1.60%)</p> <p>3</p> |
| <p>Skin and subcutaneous tissue disorders</p> <p>psoriasis</p> <p>alternative dictionary used: MedDRA 22.0</p> | | | |

| | | | |
|---|----------------------|----------------------|-----------------------|
| subjects affected / exposed occurrences (all) | 5 / 350 (1.43%) 5 | 4 / 176 (2.27%) 4 | 3 / 187 (1.60%) 4 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 6 / 350 (1.71%) 6 | 5 / 176 (2.84%) 6 | 8 / 187 (4.28%) 10 |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 350 (0.00%) 0 | 0 / 176 (0.00%) 0 | 0 / 187 (0.00%) 0 |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 4 / 350 (1.14%) 4 | 1 / 176 (0.57%) 2 | 9 / 187 (4.81%) 10 |
| musculoskeletal chest pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 2 / 350 (0.57%) 2 | 1 / 176 (0.57%) 1 | 0 / 187 (0.00%) 0 |
| psoriatic arthropathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 350 (0.00%) 0 | 1 / 176 (0.57%) 1 | 1 / 187 (0.53%) 1 |
| Infections and infestations | | | |
| bronchitis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 5 / 350 (1.43%) 5 | 3 / 176 (1.70%) 3 | 7 / 187 (3.74%) 8 |
| ear infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 350 (0.86%) 3 | 0 / 176 (0.00%) 0 | 2 / 187 (1.07%) 3 |
| nasopharyngitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|------------------------|-------------------------|-------------------------|
| subjects affected / exposed occurrences (all) | 34 / 350 (9.71%) 34 | 19 / 176 (10.80%) 22 | 32 / 187 (17.11%) 42 |
| pharyngitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 4 / 350 (1.14%) 4 | 1 / 176 (0.57%) 1 | 11 / 187 (5.88%) 12 |
| sinusitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 2 / 350 (0.57%) 2 | 3 / 176 (1.70%) 3 | 10 / 187 (5.35%) 10 |
| upper respiratory tract infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 20 / 350 (5.71%) 21 | 14 / 176 (7.95%) 19 | 25 / 187 (13.37%) 30 |
| urinary tract infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 5 / 350 (1.43%) 5 | 3 / 176 (1.70%) 3 | 5 / 187 (2.67%) 9 |
| vulvovaginal candidiasis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[14] occurrences (all) | 0 / 129 (0.00%) 0 | 1 / 66 (1.52%) 1 | 0 / 56 (0.00%) 0 |

| Non-serious adverse events | Ixe/Ixe Q12W - Maintenance Period Primary Population | Placebo Resp/Placebo - Maintenance Period Secondary Population | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop |
|--|--|--|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 87 / 181 (48.07%) | 2 / 3 (66.67%) | 77 / 155 (49.68%) |
| Investigations | | | |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 2 / 181 (1.10%) 2 | 1 / 3 (33.33%) 1 | 1 / 155 (0.65%) 1 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--|--|---|--|
| <p>muscle strain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 181 (0.55%)</p> <p>1</p> | <p>0 / 3 (0.00%)</p> <p>0</p> | <p>0 / 155 (0.00%)</p> <p>0</p> |
| <p>Nervous system disorders</p> <p>headache</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>vocal cord paresis</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>8 / 181 (4.42%)</p> <p>10</p> <p>0 / 181 (0.00%)</p> <p>0</p> | <p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p> | <p>8 / 155 (5.16%)</p> <p>14</p> <p>0 / 155 (0.00%)</p> <p>0</p> |
| <p>General disorders and administration site conditions</p> <p>asthenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site erythema</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site reaction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>2 / 181 (1.10%)</p> <p>3</p> <p>4 / 181 (2.21%)</p> <p>4</p> <p>1 / 181 (0.55%)</p> <p>13</p> <p>4 / 181 (2.21%)</p> <p>8</p> | <p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p> <p>0 / 3 (0.00%)</p> <p>0</p> | <p>1 / 155 (0.65%)</p> <p>1</p> <p>5 / 155 (3.23%)</p> <p>14</p> <p>1 / 155 (0.65%)</p> <p>5</p> <p>10 / 155 (6.45%)</p> <p>42</p> |
| <p>Reproductive system and breast disorders</p> <p>amenorrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> | | | |

| | | | |
|--|------------------------|--------------------|----------------------|
| subjects affected / exposed ^[13] occurrences (all) | 0 / 61 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 43 (0.00%) 0 |
| Gastrointestinal disorders diarrhoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 6 / 181 (3.31%) 8 | 0 / 3 (0.00%) 0 | 6 / 155 (3.87%) 6 |
| nausea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 4 / 181 (2.21%) 4 | 0 / 3 (0.00%) 0 | 6 / 155 (3.87%) 7 |
| Respiratory, thoracic and mediastinal disorders oropharyngeal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 5 / 181 (2.76%) 5 | 0 / 3 (0.00%) 0 | 2 / 155 (1.29%) 2 |
| Skin and subcutaneous tissue disorders psoriasis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 5 / 181 (2.76%) 6 | 0 / 3 (0.00%) 0 | 6 / 155 (3.87%) 8 |
| Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 10 / 181 (5.52%) 11 | 0 / 3 (0.00%) 0 | 6 / 155 (3.87%) 7 |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 181 (0.00%) 0 | 0 / 3 (0.00%) 0 | 0 / 155 (0.00%) 0 |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 6 / 181 (3.31%) 8 | 0 / 3 (0.00%) 0 | 9 / 155 (5.81%) 9 |
| musculoskeletal chest pain | | | |

| | | | |
|---|-------------------|----------------|-------------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 1 / 3 (33.33%) | 0 / 155 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 181 (0.00%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences (all) | 0 | 0 | 1 |
| Infections and infestations | | | |
| bronchitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 10 / 181 (5.52%) | 0 / 3 (0.00%) | 2 / 155 (1.29%) |
| occurrences (all) | 12 | 0 | 2 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 181 (0.55%) | 0 / 3 (0.00%) | 1 / 155 (0.65%) |
| occurrences (all) | 1 | 0 | 1 |
| nasopharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 24 / 181 (13.26%) | 0 / 3 (0.00%) | 29 / 155 (18.71%) |
| occurrences (all) | 31 | 0 | 42 |
| pharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 3 / 181 (1.66%) | 0 / 3 (0.00%) | 3 / 155 (1.94%) |
| occurrences (all) | 3 | 0 | 7 |
| sinusitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 6 / 181 (3.31%) | 0 / 3 (0.00%) | 7 / 155 (4.52%) |
| occurrences (all) | 6 | 0 | 7 |
| upper respiratory tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 21 / 181 (11.60%) | 0 / 3 (0.00%) | 20 / 155 (12.90%) |
| occurrences (all) | 23 | 0 | 23 |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|-----------------|----------------|-----------------|
| subjects affected / exposed | 7 / 181 (3.87%) | 1 / 3 (33.33%) | 8 / 155 (5.16%) |
| occurrences (all) | 9 | 1 | 8 |
| vulvovaginal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[14] | 0 / 61 (0.00%) | 0 / 2 (0.00%) | 1 / 43 (2.33%) |
| occurrences (all) | 0 | 0 | 1 |

| Non-serious adverse events | ETNResp/Placebo - Maintenance Period Secondary Population | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Population | Ixe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary Pop |
|--|--|--|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 42 / 132 (31.82%) | 106 / 200 (53.00%) | 27 / 75 (36.00%) |
| Investigations | | | |
| mycobacterium tuberculosis complex test positive | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 1 / 200 (0.50%) | 0 / 75 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injury, poisoning and procedural complications | | | |
| muscle strain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 132 (0.76%) | 1 / 200 (0.50%) | 2 / 75 (2.67%) |
| occurrences (all) | 1 | 1 | 2 |
| Nervous system disorders | | | |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 5 / 132 (3.79%) | 4 / 200 (2.00%) | 4 / 75 (5.33%) |
| occurrences (all) | 6 | 17 | 4 |
| vocal cord paresis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 132 (0.00%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 132 (0.76%) | 0 / 200 (0.00%) | 0 / 75 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|--|---|---|---|
| <p>injection site erythema</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 132 (0.76%)</p> <p>3</p> | <p>0 / 200 (0.00%)</p> <p>0</p> | <p>0 / 75 (0.00%)</p> <p>0</p> |
| <p>injection site pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 132 (0.76%)</p> <p>1</p> | <p>2 / 200 (1.00%)</p> <p>4</p> | <p>0 / 75 (0.00%)</p> <p>0</p> |
| <p>injection site reaction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 132 (0.76%)</p> <p>3</p> | <p>20 / 200 (10.00%)</p> <p>80</p> | <p>3 / 75 (4.00%)</p> <p>21</p> |
| <p>Reproductive system and breast disorders</p> <p>amenorrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[13]</p> <p>occurrences (all)</p> | <p>0 / 43 (0.00%)</p> <p>0</p> | <p>0 / 74 (0.00%)</p> <p>0</p> | <p>0 / 22 (0.00%)</p> <p>0</p> |
| <p>Gastrointestinal disorders</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nausea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 132 (0.76%)</p> <p>1</p> <p>2 / 132 (1.52%)</p> <p>2</p> | <p>5 / 200 (2.50%)</p> <p>5</p> <p>4 / 200 (2.00%)</p> <p>6</p> | <p>1 / 75 (1.33%)</p> <p>1</p> <p>1 / 75 (1.33%)</p> <p>1</p> |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 132 (0.76%)</p> <p>1</p> | <p>4 / 200 (2.00%)</p> <p>4</p> | <p>1 / 75 (1.33%)</p> <p>1</p> |
| <p>Skin and subcutaneous tissue disorders</p> <p>psoriasis</p> <p>alternative dictionary used: MedDRA 22.0</p> | | | |

| | | | |
|---|-----------------------|------------------------|---------------------|
| subjects affected / exposed occurrences (all) | 2 / 132 (1.52%) 3 | 8 / 200 (4.00%) 10 | 3 / 75 (4.00%) 5 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 8 / 132 (6.06%) 10 | 10 / 200 (5.00%) 11 | 1 / 75 (1.33%) 1 |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 132 (0.76%) 1 | 2 / 200 (1.00%) 2 | 0 / 75 (0.00%) 0 |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 2 / 132 (1.52%) 7 | 6 / 200 (3.00%) 6 | 3 / 75 (4.00%) 3 |
| musculoskeletal chest pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 132 (0.00%) 0 | 2 / 200 (1.00%) 2 | 0 / 75 (0.00%) 0 |
| psoriatic arthropathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 132 (2.27%) 4 | 1 / 200 (0.50%) 1 | 1 / 75 (1.33%) 1 |
| Infections and infestations | | | |
| bronchitis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 132 (0.00%) 0 | 10 / 200 (5.00%) 11 | 1 / 75 (1.33%) 1 |
| ear infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 132 (0.76%) 1 | 3 / 200 (1.50%) 3 | 1 / 75 (1.33%) 1 |
| nasopharyngitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|--|-------------------------|-------------------------|------------------------|
| subjects affected / exposed occurrences (all) | 19 / 132 (14.39%) 24 | 35 / 200 (17.50%) 47 | 12 / 75 (16.00%) 13 |
| pharyngitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 1 / 132 (0.76%) 1 | 7 / 200 (3.50%) 7 | 2 / 75 (2.67%) 2 |
| sinusitis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 1 / 132 (0.76%) 1 | 7 / 200 (3.50%) 7 | 1 / 75 (1.33%) 1 |
| upper respiratory tract infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 8 / 132 (6.06%) 9 | 21 / 200 (10.50%) 28 | 7 / 75 (9.33%) 10 |
| urinary tract infection alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 0 / 132 (0.00%) 0 | 8 / 200 (4.00%) 14 | 1 / 75 (1.33%) 1 |
| vulvovaginal candidiasis alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[14] occurrences (all) | 0 / 43 (0.00%) 0 | 2 / 74 (2.70%) 2 | 2 / 22 (9.09%) 2 |

| Non-serious adverse events | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W - Maintenance Relapse Population | Placebo Long-Term Extension Period |
|--|---|--|---------------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 26 / 49 (53.06%) | 136 / 368 (36.96%) | 7 / 26 (26.92%) |
| Investigations | | | |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed occurrences (all) | 0 / 49 (0.00%) 0 | 2 / 368 (0.54%) 2 | 0 / 26 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--|---|---|--|
| <p>muscle strain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 49 (0.00%)</p> <p>0</p> | <p>1 / 368 (0.27%)</p> <p>1</p> | <p>2 / 26 (7.69%)</p> <p>2</p> |
| <p>Nervous system disorders</p> <p>headache</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>vocal cord paresis</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>4 / 49 (8.16%)</p> <p>7</p> <p>0 / 49 (0.00%)</p> <p>0</p> | <p>12 / 368 (3.26%)</p> <p>19</p> <p>0 / 368 (0.00%)</p> <p>0</p> | <p>0 / 26 (0.00%)</p> <p>0</p> <p>0 / 26 (0.00%)</p> <p>0</p> |
| <p>General disorders and administration site conditions</p> <p>asthenia</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site erythema</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>injection site reaction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 49 (0.00%)</p> <p>0</p> <p>0 / 49 (0.00%)</p> <p>0</p> <p>1 / 49 (2.04%)</p> <p>2</p> <p>2 / 49 (4.08%)</p> <p>2</p> | <p>0 / 368 (0.00%)</p> <p>0</p> <p>5 / 368 (1.36%)</p> <p>6</p> <p>1 / 368 (0.27%)</p> <p>1</p> <p>19 / 368 (5.16%)</p> <p>62</p> | <p>0 / 26 (0.00%)</p> <p>0</p> <p>0 / 26 (0.00%)</p> <p>0</p> <p>1 / 26 (3.85%)</p> <p>18</p> <p>0 / 26 (0.00%)</p> <p>0</p> |
| <p>Reproductive system and breast disorders</p> <p>amenorrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> | | | |

| | | | |
|--|---------------------|------------------------|---------------------|
| subjects affected / exposed ^[13] occurrences (all) | 0 / 19 (0.00%) 0 | 0 / 129 (0.00%) 0 | 1 / 12 (8.33%) 1 |
| Gastrointestinal disorders diarrhoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 49 (6.12%) 4 | 5 / 368 (1.36%) 5 | 1 / 26 (3.85%) 1 |
| nausea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 2 / 49 (4.08%) 2 | 4 / 368 (1.09%) 4 | 0 / 26 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders oropharyngeal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 49 (6.12%) 4 | 7 / 368 (1.90%) 7 | 0 / 26 (0.00%) 0 |
| Skin and subcutaneous tissue disorders psoriasis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 49 (6.12%) 3 | 12 / 368 (3.26%) 18 | 1 / 26 (3.85%) 1 |
| Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 49 (2.04%) 1 | 13 / 368 (3.53%) 14 | 0 / 26 (0.00%) 0 |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 49 (0.00%) 0 | 1 / 368 (0.27%) 1 | 0 / 26 (0.00%) 0 |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 49 (6.12%) 3 | 12 / 368 (3.26%) 15 | 1 / 26 (3.85%) 1 |
| musculoskeletal chest pain | | | |

| | | | |
|---|-----------------|-------------------|----------------|
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 3 / 49 (6.12%) | 0 / 368 (0.00%) | 0 / 26 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Infections and infestations | | | |
| bronchitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | 11 / 368 (2.99%) | 1 / 26 (3.85%) |
| occurrences (all) | 3 | 11 | 1 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | 1 / 368 (0.27%) | 0 / 26 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| nasopharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 8 / 49 (16.33%) | 41 / 368 (11.14%) | 0 / 26 (0.00%) |
| occurrences (all) | 11 | 61 | 0 |
| pharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 4 / 49 (8.16%) | 11 / 368 (2.99%) | 0 / 26 (0.00%) |
| occurrences (all) | 5 | 13 | 0 |
| sinusitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 49 (0.00%) | 12 / 368 (3.26%) | 0 / 26 (0.00%) |
| occurrences (all) | 0 | 12 | 0 |
| upper respiratory tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 7 / 49 (14.29%) | 21 / 368 (5.71%) | 2 / 26 (7.69%) |
| occurrences (all) | 9 | 32 | 4 |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 3 / 49 (6.12%) 3 | 4 / 368 (1.09%) 5 | 1 / 26 (3.85%) 1 |
| vulvovaginal candidiasis alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[14] occurrences (all) | 0 / 19 (0.00%) 0 | 1 / 129 (0.78%) 1 | 0 / 12 (0.00%) 0 |

| Non-serious adverse events | Ixe Long-Term Extension Period | Total Ixe Long-Term Extension Period | Placebo Post- Treatment Follow-Up |
|--|-----------------------------------|---|--------------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 345 / 979 (35.24%) | 345 / 1002 (34.43%) | 2 / 16 (12.50%) |
| Investigations | | | |
| mycobacterium tuberculosis complex test positive alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 5 / 979 (0.51%) 5 | 5 / 1002 (0.50%) 5 | 0 / 16 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| muscle strain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 16 / 979 (1.63%) 17 | 16 / 1002 (1.60%) 17 | 0 / 16 (0.00%) 0 |
| Nervous system disorders | | | |
| headache alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 30 / 979 (3.06%) 46 | 30 / 1002 (2.99%) 46 | 0 / 16 (0.00%) 0 |
| vocal cord paresis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 979 (0.00%) 0 | 0 / 1002 (0.00%) 0 | 1 / 16 (6.25%) 1 |
| General disorders and administration site conditions | | | |
| asthenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 979 (0.31%) 3 | 3 / 1002 (0.30%) 3 | 0 / 16 (0.00%) 0 |

| | | | |
|--|---|---|---|
| <p>injection site erythema</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>5 / 979 (0.51%)</p> <p>19</p> | <p>5 / 1002 (0.50%)</p> <p>19</p> | <p>0 / 16 (0.00%)</p> <p>0</p> |
| <p>injection site pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 979 (0.10%)</p> <p>21</p> | <p>1 / 1002 (0.10%)</p> <p>21</p> | <p>0 / 16 (0.00%)</p> <p>0</p> |
| <p>injection site reaction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>21 / 979 (2.15%)</p> <p>404</p> | <p>21 / 1002 (2.10%)</p> <p>404</p> | <p>0 / 16 (0.00%)</p> <p>0</p> |
| <p>Reproductive system and breast disorders</p> <p>amenorrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[13]</p> <p>occurrences (all)</p> | <p>2 / 313 (0.64%)</p> <p>2</p> | <p>2 / 324 (0.62%)</p> <p>2</p> | <p>0 / 6 (0.00%)</p> <p>0</p> |
| <p>Gastrointestinal disorders</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nausea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>20 / 979 (2.04%)</p> <p>21</p> <p>11 / 979 (1.12%)</p> <p>11</p> | <p>20 / 1002 (2.00%)</p> <p>21</p> <p>11 / 1002 (1.10%)</p> <p>11</p> | <p>0 / 16 (0.00%)</p> <p>0</p> <p>0 / 16 (0.00%)</p> <p>0</p> |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>12 / 979 (1.23%)</p> <p>15</p> | <p>12 / 1002 (1.20%)</p> <p>15</p> | <p>0 / 16 (0.00%)</p> <p>0</p> |
| <p>Skin and subcutaneous tissue disorders</p> <p>psoriasis</p> <p>alternative dictionary used: MedDRA 22.0</p> | | | |

| | | | |
|---|------------------------|-------------------------|---------------------|
| subjects affected / exposed occurrences (all) | 28 / 979 (2.86%) 31 | 28 / 1002 (2.79%) 31 | 0 / 16 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 48 / 979 (4.90%) 60 | 48 / 1002 (4.79%) 60 | 0 / 16 (0.00%) 0 |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 4 / 979 (0.41%) 4 | 4 / 1002 (0.40%) 4 | 0 / 16 (0.00%) 0 |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 40 / 979 (4.09%) 50 | 40 / 1002 (3.99%) 50 | 0 / 16 (0.00%) 0 |
| musculoskeletal chest pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 3 / 979 (0.31%) 3 | 3 / 1002 (0.30%) 3 | 0 / 16 (0.00%) 0 |
| psoriatic arthropathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 5 / 979 (0.51%) 6 | 5 / 1002 (0.50%) 6 | 0 / 16 (0.00%) 0 |
| Infections and infestations | | | |
| bronchitis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 38 / 979 (3.88%) 52 | 38 / 1002 (3.79%) 52 | 0 / 16 (0.00%) 0 |
| ear infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 12 / 979 (1.23%) 15 | 12 / 1002 (1.20%) 15 | 1 / 16 (6.25%) 1 |
| nasopharyngitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|--------------------|---------------------|----------------|
| subjects affected / exposed | 125 / 979 (12.77%) | 125 / 1002 (12.48%) | 0 / 16 (0.00%) |
| occurrences (all) | 195 | 195 | 0 |
| pharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 19 / 979 (1.94%) | 19 / 1002 (1.90%) | 0 / 16 (0.00%) |
| occurrences (all) | 26 | 26 | 0 |
| sinusitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 38 / 979 (3.88%) | 38 / 1002 (3.79%) | 0 / 16 (0.00%) |
| occurrences (all) | 56 | 56 | 0 |
| upper respiratory tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 108 / 979 (11.03%) | 108 / 1002 (10.78%) | 0 / 16 (0.00%) |
| occurrences (all) | 166 | 166 | 0 |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 27 / 979 (2.76%) | 27 / 1002 (2.69%) | 0 / 16 (0.00%) |
| occurrences (all) | 30 | 30 | 0 |
| vulvovaginal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[14] | 3 / 313 (0.96%) | 3 / 324 (0.93%) | 0 / 6 (0.00%) |
| occurrences (all) | 3 | 3 | 0 |

| Non-serious adverse events | ETN Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up |
|---|------------------------------|-----------------------------------|----------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 3 / 6 (50.00%) | 21 / 248 (8.47%) | 34 / 656 (5.18%) |
| Investigations | | | |
| mycobacterium tuberculosis complex test positive | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 2 / 656 (0.30%) |
| occurrences (all) | 0 | 0 | 2 |
| Injury, poisoning and procedural complications | | | |
| muscle strain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 248 (0.40%) 1 | 0 / 656 (0.00%) 0 |
| Nervous system disorders headache alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 1 / 248 (0.40%) 2 | 1 / 656 (0.15%) 1 |
| vocal cord paresis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 248 (0.00%) 0 | 0 / 656 (0.00%) 0 |
| General disorders and administration site conditions asthenia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 0 / 248 (0.00%) 0 | 0 / 656 (0.00%) 0 |
| injection site erythema alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 248 (0.00%) 0 | 0 / 656 (0.00%) 0 |
| injection site pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 0 / 248 (0.00%) 0 | 0 / 656 (0.00%) 0 |
| injection site reaction alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 248 (0.00%) 0 | 0 / 656 (0.00%) 0 |
| Reproductive system and breast disorders amenorrhoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed ^[13] occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 78 (0.00%) 0 | 0 / 203 (0.00%) 0 |
| Gastrointestinal disorders | | | |

| | | | |
|--|---------------------|----------------------|----------------------|
| diarrhoea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 248 (0.40%) 1 | 0 / 656 (0.00%) 0 |
| nausea alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 1 / 248 (0.40%) 1 | 2 / 656 (0.30%) 2 |
| Respiratory, thoracic and mediastinal disorders oropharyngeal pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 0 / 248 (0.00%) 0 | 1 / 656 (0.15%) 1 |
| Skin and subcutaneous tissue disorders psoriasis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 248 (1.21%) 3 | 6 / 656 (0.91%) 6 |
| Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 3 / 248 (1.21%) 3 | 5 / 656 (0.76%) 5 |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 1 / 6 (16.67%) 1 | 1 / 248 (0.40%) 1 | 0 / 656 (0.00%) 0 |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 6 (0.00%) 0 | 1 / 248 (0.40%) 1 | 0 / 656 (0.00%) 0 |
| musculoskeletal chest pain alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 0 / 656 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| psoriatic arthropathy | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 4 / 656 (0.61%) |
| occurrences (all) | 0 | 0 | 4 |
| Infections and infestations | | | |
| bronchitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 3 / 248 (1.21%) | 3 / 656 (0.46%) |
| occurrences (all) | 0 | 3 | 3 |
| ear infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences (all) | 0 | 0 | 1 |
| nasopharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 1 / 6 (16.67%) | 3 / 248 (1.21%) | 4 / 656 (0.61%) |
| occurrences (all) | 1 | 3 | 4 |
| pharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 3 / 248 (1.21%) | 2 / 656 (0.30%) |
| occurrences (all) | 0 | 4 | 2 |
| sinusitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 1 / 248 (0.40%) | 3 / 656 (0.46%) |
| occurrences (all) | 0 | 1 | 3 |
| upper respiratory tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 6 (0.00%) | 2 / 248 (0.81%) | 4 / 656 (0.61%) |
| occurrences (all) | 0 | 2 | 4 |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|---------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 6 (0.00%) | 0 / 248 (0.00%) | 1 / 656 (0.15%) |
| occurrences (all) | 0 | 0 | 1 |
| vulvovaginal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[14] | 0 / 1 (0.00%) | 0 / 78 (0.00%) | 0 / 203 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Ixe Q12W Post-Treatment Follow-Up | | |
|---|-----------------------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| Investigations | | | |
| mycobacterium tuberculosis complex test positive | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injury, poisoning and procedural complications | | | |
| muscle strain | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nervous system disorders | | | |
| headache | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| vocal cord paresis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| injection site erythema | | | |

| | | | |
|--|---|--|--|
| <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 24 (0.00%)</p> <p>0</p> | | |
| <p>injection site pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 24 (0.00%)</p> <p>0</p> | | |
| <p>injection site reaction</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 24 (0.00%)</p> <p>0</p> | | |
| <p>Reproductive system and breast disorders</p> <p>amenorrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed^[13]</p> <p>occurrences (all)</p> | <p>0 / 10 (0.00%)</p> <p>0</p> | | |
| <p>Gastrointestinal disorders</p> <p>diarrhoea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nausea</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 24 (0.00%)</p> <p>0</p> <p>0 / 24 (0.00%)</p> <p>0</p> | | |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>oropharyngeal pain</p> <p>alternative dictionary used: MedDRA 22.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 24 (0.00%)</p> <p>0</p> | | |
| <p>Skin and subcutaneous tissue disorders</p> <p>psoriasis</p> <p>alternative dictionary used: MedDRA 22.0</p> | | | |

| | | | |
|---|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| arthritis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| back pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| musculoskeletal chest pain alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| psoriatic arthropathy alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| Infections and infestations | | | |
| bronchitis alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| ear infection alternative dictionary used: MedDRA 22.0 subjects affected / exposed occurrences (all) | 0 / 24 (0.00%) 0 | | |
| nasopharyngitis alternative dictionary used: MedDRA 22.0 | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| pharyngitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| sinusitis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| upper respiratory tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | | |
| occurrences (all) | 0 | | |
| vulvovaginal candidiasis | | | |
| alternative dictionary used: MedDRA 22.0 | | | |
| subjects affected / exposed ^[14] | 0 / 10 (0.00%) | | |
| occurrences (all) | 0 | | |

Notes:

[13] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

[14] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male and female subjects. The number of subjects exposed has been adjusted accordingly.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 15 March 2012 | Changes to protocol (a) are as follows: <ul style="list-style-type: none"> o Including monthly urine pregnancy testing for women of childbearing potential o Clarifying under "Treatment Assignment for Non-Responders" that patients who have no response. o Removing evaluation of joint pain as a secondary objective o Added a definition of concomitant topical products o Changing the definition of "rebound" to add an evaluation of PASI so that rebound is now defined o Stratifying randomization by center, changing the primary analyses for categorical efficacy outcomes to a Cochran-Mantel-Haenszel (CMH) test stratified by center, specifying the pooling strategy o Using a MMRM approach for the primary analysis of continuous variables o Revised enrollment criteria to exclude participants who are positive for hepatitis B surface antigen or positive for anti-hepatitis B core antibody o Added new exclusion criterion and discontinuation criteria, revised hepatic safety monitoring rules and lab tests, and a discontinuation rule for participants who develop symptoms of lupus-like syndrome |
| 31 October 2012 | Changes to protocol (b) are as follows: <ul style="list-style-type: none"> o Modified exclusion criterion to allow enrollment of patients who have had previous infection with hepatitis B virus (HBV) o Added discontinuation requirement for positive HBV DNA test results o Added section of hepatitis B monitoring o Corrected inclusion criterion to require use of spermicide in conjunction with a diaphragm o Clarified exclusion criterion to define participants with serious cardiac conditions o Clarified descriptions of premedication to indicate that acceptable medications are not restricted to the examples given o Updated the PASI 75 assumption for etanercept at Week 12 to 53% |
| 04 February 2015 | Changes to protocol (c) are as follows: <ul style="list-style-type: none"> o Modified treatment administered in the Long-Term Extension Period o Modified existing text regarding the discontinuation of placebo injections after the study is unblinded o Modified the requirements for discontinuation of inadvertently enrolled participants o Modified permitted concomitant medications o Modified concomitant medications o Modified language on permitted concomitant medication and the permitted drug delivery devices |
| 28 March 2017 | Changes to protocol (d) are as follows: <p>Added IBD adjudication consistent with compound-level decision as IBD, specifically Crohn's Disease and ulcerative colitis, has been demonstrated to occur more frequently in people with psoriasis. IBD is a reasonably anticipated event</p> <p>Added clarity on dosing windows for Long-Term Extension Period</p> |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported